Curaçao Access to OilWell Cannabis Houston’s 16,590mg 7-Cannabinoid THCa RSO Sublingual Oil with Patient-Controlled 1,500mg THCa-to-THC Activation, ABC13-Featured Open-Source Formula from Bentley’s 10-Year Miracle Legacy – International Shipping

Rick Simpson Oil (RSO) na Kòrsou: Guía Kompleto di OilWell Cannabis

Pa desennanan, hendenan banda tur Kòrsou a buska alternativa ora e médiko konvensional no ta traha. Si bo ta na Willemstad luchando ku dolor kroniko despues di añanan di trabou físiko, un cuidadó na Sint Michiel buskando apoyo pa un ser keridu bao kimoterapia, o algu na Band’abou explorando opcion natural pa durmiòf o ansiedat, bo seguro a tende burachinan tokante Rick Simpson Oil. Quizás bo a mira é menshoná den foro online, o un amigo ku a biaha pa Merca a trese historia tokante e poderoso ekstrak di kanábishiku. E portada tin peso—pero kiko e ta eksaktamente? Unde a yega for di? Y mas importante, kiko bo por hasi pa haña un version segura, legal, y informá cientificamente aki na Kòrsou sin navigá e konfushon y riesgonan ku histórikamente a rodomá e producto?

Nos a krea e guía aki pasobra Kòrsou mester tin edukashon honesto, basá na evidensia tokante RSO. Nos kompañía, OilWell Cannabis, por ta base na Houston, Texas, pero nos misión traspasa frontera. Nos a krea un línia di producto ku honra e espíritu grassroots di visión original di Rick Simpson mientras nos ta solushona e problema di siguridat, kalidat, y legal ku a hasa RSO tradisional no konfiable. Pa residentenan di Kòrsou—un lugar unda akseso na kuido médiko por ta limitá, unda e klima tropical aklara degradashon di producto, y unda actitúd cultural tokante kanábishiku ta evolucioná—entendé e diferensianan aki no ta solamente útil. Ta esensial.

Esto no ta otro artíkulo genérico tokante kanábishiku. E ta un rekursu kompleto, listo pa publikashon ku konektá e historia global di RSO direkto na bo realidat na Kòrsou. Lo nos laga bo sa e historia, e siensia, e marco legal ku ta hasa nos producto aksesibel pa bo, i eksaktamente kiko nos fórmula ta traha. Tur reklamashon ta apoyá pa investigashon revisá pa par. Tur detaye tokante nos producto ta transparente. Y lo mas importante, lo nos mustra kiko bo hasi pa tuma desishon informá—sea bo komprá for di nos o usa nos fórmula open-source pa krea bo mes medicina aki na Kòrsou.

TOKANTE RICK SIMPSON I RSO TRADISIONAL

Ken ta Rick Simpson?

Rick Simpson a nase na 1949 na Amherst, Nova Scotia, Canada. No ta un dokter, siensiatiko, ni profesional médiko. Ta un inginiero di poder i trahadó di mantenimiento—un trahadó di kola blù ku su kaminda den abogashí di kanábishiku a kuminsá no ku investigashon pero ku sufrimentu personal y un deskonfiansa fondo den e sistema médiko ku a faya é. Pa residentenan di Kòrsou ku a experimenta largu warda na SEHOS (St. Elizabeth Hospital) o a sinti ignorá dor di dokternan ku no por a splika nan dolor kroniko, storia di Simpson ta resoná kultura tras di geografía.

Na 1997, mientras ta trahando na un hospital na Moncton, New Brunswick, Simpson a kai for di un andamiaje y a sufri un lesa serio den su kabes. E konsekuensia a inklui tinnitus persistente, mareo, y un konstalashon di síntoma post-konkokshón ku e médiko konvensional no por a resolve adegua. Segun Simpson, e medikamentu ku a wordu preskríbí pa é no por a yuda o a has su kondishon peor. É a rapportá ku kanábishiku a duna mas alivio ku kualkier otro kos ku su dokter ofrecé, pero ora el a pidi su dokter pa apoyá o preskríbí kanábishiku, e petishon a worde refusá .

Interés di Simpson den asietá di kanábishiku a profundisá despues ku el a tende tokante un estudia 1974 finansiá dor di National Institute of Health i konsutá na Medical College of Virginia, unda THC a worde rapportá pa lenta o shrink tumor den ratón. E studia—originalmente intensioná pa mustra daño—a bira un punto di referensia fundeshonal den abogashí di Simpson despues, aunke su hamentu nan a nunka worde replicá en trial kliniko kontrolá humanu .

E momentu pivotal den storia di Simpson a yega na 2003. É a rapportá ku tres kapi bonchi riba su braza a worde diagnosticá dor di su dokter komo karsinoma basal. Maske di perseguí trata konvensional, Simpson a apliká asietá di kanábishiku konesentrá direk riba e lesnan, tap’é ku bandashi, i warda. Segun su kuento, e bonchinan a desaparesé den kuater dia. Ningun verifikashon médiko independiente di e resulta aki a wordu publiká, y ningun konfirmashon biopsia o seguimento kliniko a wordu dokumentá en kualkier füente revisá pa par. Sinembargo, e experiensia personal aki a bira e storia di origen di Rick Simpson Oil y e fundashon di tur kos ku a sigui .

Konteksto importante: Kuento di Simpson ta presentá aki komo su testigu personal. E ausensia di dokumentashon kliniko, observashon kontrolá, o konfirmashon médiko independiente no por permití evaluá e evento nan komo evidensia médika. Nan ta, sinembargo, histórikamente significante komo katalisador pa un moveshi global. Pa lesadónan di Kòrsou ku por depende hopi riba informashon di boka-a-boka den komunidad chikí, entendé e diferensia entre un storia personal kompelente i prueba médika ta krusial.

E krusada—spreading the oil

Despues di su experiensia na 2003, Simpson a kumeté su mes totalmente na produhí i distribushon di asietá di kanábishiku konesentrá. Operando for di su propiedat na Maccan, Nova Scotia, é a kuminsá hasi e asietá na kantidat grandi i dun’é for free pa pashientenan di kansèr i otro den su komunidad. É no a kobra nada. Segun su mesun kuento, é a yuda desennan di hende ku kondishonan inkluyendo kansèr, dolor kroniko, diabetes, infección, gloukoma, artritis, depreshon, insomnio, y otro .

Storia di Simpson a yega un audiensia global dor di e dokumentario 2005 Run From The Cure, dirí dor di Christian Laurette. E fílm a dokumentá reklamashonnan di Simpson, a mustra testigu di hende ku é a trata, i a frame su trabou komo un desafío grassroots na interesnan farmaséutiko i guvernamental. A worde distribuí for free online i a bira uno di e fílmanan di abogashí di kanábishiku mas kompartí di su époka. Den komunidad di kanábishiku, tabata fundashonal—pa hopi hende, Run From The Cure tabata nan introdukshon na e konsepto di asietá di kanábishiku konesentrá komo medicina .

Abogashí di Simpson a wòrdu konflíto direkto ku ley Kanadian. Royal Canadian Mounted Police (RCMP) a reydá su propiedat na 2005, konfiská planta i ekipo. É a worde akusá ku kultivashon, posesión, i trafficking di kanábishiku. A pesar di apoyo di komunidad i atenshon públiko, é a worde reydá otro biaha na 2009. É a worde absolvé di algun akusashon pero kondensá riba otro. Enfrentando presion legal kontinuá, Simpson eventualmente a laga Canada i re-lokalisá na Europa, biví na Croasia i despues na Hulanda, unda é a kontinuá su abogashí for di afó .

Na 2012, Simpson a publiká Phoenix Tears: The Rick Simpson Story, un buki ku detaya su experiensia personal, su proseso di hasi asietá, y su bishón filosófiko mas amplio tokante kanábishiku, médika, i supreshon institushonal. Tambe a mantené phoenixtears.ca komo su platfroma primario online pa informashon i abogashí .

Durante su karera públiko, posishon di Simpson a keda konsistente i inkomprometedor: é a mantené ku asietá di kanábishiku—partikularmente asietá ku altu THC hasi segun su método spesífiko—por kura kansèr i hopi otro enfermedat, i ku kompañia farmaséutiko, agensia guvernamental, i institushonnan médiko tabata aktivamente suprimes e konosementu aki pa protega nan interesnan finansiero. É a frame su trabou no solamente komo abogashí pa salú pero komo un lucha kontra korupshon institushonal .

Konteksto importante: E frame konspirativo di Simpson ta notá aki sin endosashon o desmishon. Ta reflektá un mundo bishón kompartá pa hopi den e moveshi di kanábishiku tempran y ta relevante pa entendé kiko RSO a bira culturalmente significante. Na Kòrsou, unda hopi residente a experimenta bareranan sistemátiko den kuido médiko o a sinti no wordu tendí dor di autoridatnan, e perspektiva aki por resoná fuerte—pero mester wordu balansá ku realidat siéntifiko.

E protocol tradisional di RSO—regimen di 60 gram, 90 dia di Simpson

Simpson su rekomendashon di trata principal tabata un protocol oral strukturá diseñá pa entregá un total di 60 gram (aproximadamente 60 mL) di asietá di kanábishiku konesentrá riba periodo di aproximadamente 90 dia. É a deskirí esaki komo un protocol di trata di kansèr, aunke é tambe a rekomendá é pa otro kondishon numeroso. E siguiente ta un brekdown detayá di e protocol segun Simpson a deskirí é .

Meta

Konsumí 60 gram di asietá di kanábishiku konesentrá, altu-THC riba aproximadamente 90 dia. Simpson a konsiderá esaki e kantidat mínimo nesesario pa un kors di trata serio di kansèr.

Skedula di titrashon

• Siman 1: Kuminsá ku un dosis aproximadamente e tamaño di mitar granu di aros seku—aproximadamente 10 te 15 miligram di asietá—konsumí tres biaha pa dia (mañan, atardi, i promé di drumi). Total di konsumo diario durante e fase aki: aproximadamente 30 te 45 miligram. Simpson a enfatisa ku e dosnan inicial mester ta masha chikí pa e kuerpo por kuminsá adjustá na e efekto psikoaktivo di THC.

• Simanan 2 te 5: Dublá e dosis aproximadamente kada kuater dia. E meta di e rampa lento tabata konstruí toleransia na THC gradualmente i minimiza disrupshon for di e efektonan psikoaktivo. Na final di e periodo di eskalashon aki—aproximadamente kuater te sinku siman—e meta tabata yega aproximadamente 1 gram (1,000 miligram) di asietá pa dia, dividí en tres dosis mas o menos igual.

• Simanan 5 te 12: Mantené e dosi kompleto di aproximadamente 1 gram pa dia, dividí en tres dosis di aproximadamente 333 miligram kada un, i kontinuá te e 60 gram kompleto a wordu konsumí. Na e nivel di dosis aki, e 50-plus gram restante di asietá lo worde konsumí den e siete te ocho siman final.

Métodonan di administrashon

• Método primario—oral: Simpson a rekomendá pa pone e dosis direk bou di lenga (sublingual) o trank’é. É a konsiderá ingestá oral e ruta mas importante pa absorpshon sistémiko y e método primario pa kanser interno i otro kondishon sistémiko.
• Método sekundario—tópiko: Pa kanser di piel i lesnan eksterno, Simpson a rekomendá apliká e asietá direk riba e area afektá, tap’é ku un bandashi, i kambio e bandashi kada tres te kuater dia. É a kombiná aplikashon tópiko ku dosis oral pa kanser di piel.
• No rekomendá komo primario—inhala: Simpson no a rekomendá fuma o vaporisá e asietá komo método di trata primario. É a konosé inhalashon pa alivio inmediato di síntoma (dolor, nausea) pero a mantené ku e ruta oral tabata nesesario pa e eksposhon sostenido, altu-dosis ku é a konsiderá terapéutikamente esensial.

Toleransia i e efekto psikoaktivo

• Simpson a mantené ku pashientenan lo desaroyá toleransia significante na e efekto psikoaktivo di THC den aproximadamente tres te kuater siman di dosis konsistente ku eskalashon.
• É a konsiderá e efektonan euforiko, sedativo, o disorienta un efekto sekundario menor i temporal i a urge pashientenan fuerte pa no laga e hòchi disimulé nan pa kontinuá ku e protocol.
• É a rekomendá pa pashientenan tuma nan dosnan inicial na nochi o promé di drumi pa drumi door di e efekto nan psikoaktivo mas intensivo durante e fase inicial di titrashon.
• Simpson tambe a rekomendá pa pashientenan evitá guine of operá maquinaria durante e periodo di titrashon i ku nan a informá miembronan di família tokante kiko e prueba.

Mantenimiento despues di protocol

• Despues di kompletá e kors kompleto di 60 gram, Simpson a rekomendá un dosis di mantenimiento di aproximadamente 1 te 2 gram di asietá pa luna, konsumí indefinidamente.
• É a konsiderá e dos di mantenimiento aki important pa salú a largu plazo i prevenshon di kansèr.
• Simpson a indiká ku dosis di mantenimento tabata hopi mas baha ku e dosis di trata i ku pashientenan ku a kompletá e protocol kompleto lo tin sufisiente toleransia na THC pa manejé komodamente.

Rekomendashonnan di dieta i stilo di bida

• Simpson tambe a abogá pa kambionan dieta hunto ku e protocol di asietá, inkluyendo redukí kantidat di sukèr, evitá kome procesá, i mehorá nutrisyon general.
• É no tabata spesífiko o sistemátiko tokante e protocolnan dieta kompará ku su protocol asietá altamente detayá—konseho dieta tabata sekundario i general.

Konteksto importante pa evaluá e protocol aki

E protocol aki tabata diseñá dor di un hende basá riba su experiensia personal i observashon anekdótiko. No tabata desaroyá door di trial kliniko, estudia di haya dosis, modelashon farmacokinétiko, o kualkier proseso formal di investigashon. Varios punto krítiko apliká:

• Ningun validashon di trial kontrolá. No tin trial kontrolá randomisá, estudia cohorte, o aun kuantu series di kaso bon dokumentá evaluando e protocol spesífiko di 60 gram/90 dia pa kualkier tipo di kansèr o kualkier otro kondishon.
• Asume materia krudo, no estandarizá. E kantidat di 60 gram ta asumi un ekstrak dominá di single-strain, THC dominante sin potensia estandarizá. Kontenido real di THC pa gram di RSO tradisional variá amplamente dependiendo di e materia planta original i téknika di ekstrashon.
• Eksposhon THC hopi haltu. Na e fase di piko di dosis, pashientenan tabata konsumí aproximadamente 1 gram di asietá altu-THC pa dia. Asumi ku RSO tradisional kontené 60 te 90 porsiento THC, esaki ta tradusí na aproximadamente 600 te 900 miligram di delta-9 THC pa dia—un dosis hopi mas haltu ku kualkier kos ku a wordu studiá en setting kliniko kontrolá. Pa kontekst, e fármaséutiko sintétiko di THC aproba dor di FDA, dronabinol, tipikamente dosifica na 2.5 te 20 miligram pa dia.
• Riesgonan real na e dosisnan aki. Konsumí 600 te 900 miligram di THC pa dia trese riesgonan serio inkluyendo intoxikashon severo, impair, ansiedat, pániko, taquicardia, hipotenshon, i desorden di úso di kanábishiku. E riesgonan aki ta ben dokumentá den seksion GENERAL KNOWLEDGE di e dokumento aki [1][13][14][15].
• Konteksto onkológiko. Pashientenan ku kansèr aktivo frecuentemente ta médikamente komplejo. Uza asietá di kanábishiku no regulá, no estandarizá komo trata primario di kansèr—potensialmente en lugar di terápianan prová—introdusé daño ku ta traspasa e mesun asietá.

Pa residentenan di Kòrsou ku ta konsiderá kualkier producto di kanábishiku pa kondishon médiko serio, e evaluashon di protocol aki ta krusial. Si bo ta traha ku onkologo na SEHOS o buskando kuido door di bo sistema médiko lokal, entendé ku método di Simpson nunka a wordu validá klinikamente ta yudabo tin konversashonnan informá ku bo ekipo médiko. RSO tradisional tabata un producto di su tempo—nase for di desesperashon ora investigashon legal no tabata posibel. Awendia, nos por hasi mehor.

Kiko ta RSO tradisional—e producto

RSO tradisional ta referí na e tipo spesífiko di asietá konesentrá di kanábishiku ku Simpson a hasi i abogá. Tabata definí no pa spesifikashon lab o standard regulatório pero pa su método i materianan. E siguiente ta deskribí e producto manera Simpson a produk’é .

Materia fuente

Simpson a usa variidatnan di kanábishiku altu-THC, dominá pa índika. É a preferí spesífikamente jenétika índika pesá, sedativo i jenéralmente a rekomendá kontra variidatnan dominá pa sativa pa trata di kansèr, kreyendo ku variidatnan índika produkí mehor resulta terapéutiko. É a kosechá su mes kanábishiku o haya’é di kosechadónan ku é a konfia. No tabata estandarizashon di strain—e materia inicial variá segun disponibilidat i temporada di kosecha.

Solvent di ekstrashon

Simpson originalmente a usa nafta—un solvent base di petróleo komersialmente disponibel komo fluido di chénder, Varsol, o producto similar. Despues tambe a endosá alcohol isopropyl 99 porsiento komo alternativa aseptabel. É a advís eksplísitamente kontra uza otro solvent, inkluyendo butano o acetona, debi na preokupashon di siguridat i pureza. Ni nafta ni alcohol isopropyl ta un solvent di grado alimentario, ku ta un asunto di siguridat significante diskutí mas abou.

Proseso di ekstrashon

1. Materia di planta kanábishiku seku o semi-seku a wordu poni den un kontendor (tipikamente un bak).
2. E materia a wordu tapá ku solvent i agitá òf revolví pa varios minuut pa disolvé kanabinoid i otro komponé soluble na grasa for di e planta.
3. E solvent a worde despará for di trawi un filtro, tipikamente tela di keshi òf un material mesh similar, den un vaso di kolecshon separado.
4. E proseso a worde ripití un segunda biaha ku solvent fresco riba e mesun materia planta pa ekstraké kanabinoid restante.
5. E labadonan solvent kombiná—awor un likidù skur, ríkí di kanabinoid—a worde poni den un rice cooker òf aparato similar di kalentamentu ku buki habri.
6. E solvent a worde evaporá na temperatura relativamente abou. Simpson a rekomendá un rice cooker spesífikamente pasobra mantené un rango di temperatura ku evapora e solvent sin pasa e punto unda kanabinoidnan degradá significantemente. Sinembargo, e temperatura aki tabata abou sufisiente pa deskarboxilá THCa den THC i pa destruí mayoria di terpeno volátil.
7. Mientras e solvent a evaporá, un asietá dik, skur a keda na fondo di e vaso.
8. E asietá final a worde transferí den syringe oral pa almacenashon i dosis.

Apariensia i karakterístika físiko

RSO tradisional tabata un asietá dik asina skur—kasi pret—visuoso, komo alquitrán. Tabata tin un olor fuerte di kanábishiku i por a transportá un olor residual di solvent dependiendo di kuanto e solvent a worde purgá kompletamente. Konsistensia tabata pegañoso i difísil di manejá na temperatura kamber, pero a bira mas fluido ora kalentá un tiki.

Perfil di kanabinoid

• Primariamente delta-9 THC deskarboxilá. E kalor involví den evaporashon di solvent a konvertí esensialmente tur THCa den ekstrak den delta-9 THC. RSO tradisional tabata por ta un producto aktiva, dominá di THC.
• Kanabinoid menor natural. Kualkier CBD, CBN, CBC, CBG, i otro kanabinoid menor ku e strain fuente a kontené tabata presente na nan proporcion natural, pero nan no tabata kontrolá, midi, òf blòk.
• Ningun kontrol di proporcion. No tabatin habilidat pa adjustá òf estandarizá proporcion spesífiko di kanabinoid. E perfil tabata determená kompletamente dor di jenétika i kondishonnan di kosecha di e planta fuente.
• Kontenido stimá di THC. Dependiendo di e materia inicial, RSO tradisional probablemente a variá entre aproximadamente 60 te 90 porsiento THC total pa peso, aunke esaki nunka a worde verifiká den konteksto di produkshon tradisional.

Kontenido di terpeno

Mínimo te nada. E kombinashon di ekstrashon ku solvent (ku disolvé terpeno den e solvent hunto ku kanabinoid) i e prosesu subsekiente di evaporashon di kalor haltu (ku volatilizá terpeno na temperatura bon bao di threshold di degradashon di kanabinoid) a signifiká ku RSO tradisional efektivamente a wordu privá di su kontenido terpeno. Esaki ta un diferensia importante pa fórmula modern ku deliberatemente preserva òf re-introdusé terpeno.

Estandardisashon i test

Nada. kada produkshon di RSO tradisional tabata diferente pasabra depende kompletamente di e materia planta inicial, kondishonnan di kosecha, pureza di solvent, téknika di ekstrashon, temperatura i durashon di evaporashon, i proseso di e hacedó individual. Simpson a opera prome di legalisashon di kanábishiku i e infrastrukturnan di test lab estandarizá ku a yega ku dje. No tabatin Certificate of Analysis, kuantifikashon di kanabinoid, òf screening di kontaminante.

Risko di solvent residual

Esey ta un di e preokupashonnan di siguridat mas significante ku produkshon tradisional di RSO. Nafta i alcohol isopropyl no ta solvent di grado alimentario. Nafta en partikular ta un mezcla kompleho di hidrokarburo di petrolio ku por kontené benzene, toluene, i otro komponé klasifiká komo tóksiko òf karsinogéniko. Purga inkompleto di solvent—ku ta difísil pa verifiká sin ekipo di kimika analítiko—ta laga residu potensialmente dañoso den e asietá finish. Métodonan moderno di ekstrashon uza etanol di grado alimentario òf CO₂ superkritiko spesífikamente pa adreshá e problema aki.

Pa residentenan di Kòrsou ku ta konsiderá produkshon DIY di RSO den e kalor tropical, e preokupashon di siguridat aki ta amplifiká. Evaporashon di solvent en ambiente haltu-humedidat ta impredecibel, i sin ventilashon adegua (partikularmente den kas antiguo Karibeño), e riesgonan di kalor i toksisidat ta substansial. Esto no ta teóriko—aksidentenan di ekstrashon di kas a oko mundialmente, i e klima Karibeño ta agregá desafío úniko.

Reklamashonnan di Simpson vs. rekord di evidensia

Rick Simpson a has reklamashonnan terapéutiko amplio tokante su asietá. É a bisa ku RSO por kura kansèr—inkluyendo kaso terminal—i ku tabata efektivo kontra diabetes, dolor kroniko, infección, gloukoma, artritis, depreshon, insomnio, sklerosis múltiple, i otro kondishon numeroso. É tabata adamante, konsistente, i públiko tokante e reklamashonnan aki durante su karera di abogashí .

Ta importante evaluá e reklamashonnan aki kontra e base di evidensia real, uza mesun standard apliká door di henter e dokumento aki.

Kiko Simpson no tabata

Simpson no tabata un siensiatiko, dokter, farmakólogo, òf investigador. No tabatin entrenamento formal den médika, onkoloxía, farmakología, òf metodología di investigashon kliniko. Nunka a diseña, kondusí, finansia, òf publiká un trial kliniko. Nunka a sushèté su resultadónan pa revisión pa par. Su base di evidensia entero tabata consistí di experiensia personal, resultadó di pashientenan auto-raportá, i testimonio rekolectá informalmente—sin kontrol, sin verifikashon independiente, sin konfirmashon di imágen, sin seguimento a largu plazo, i sin blinding.

Kiko e literatura prekliniko mustra

E literatura prekliniko kanabinoid-kansèr eksiste, i ta siéntifikamente interesante:

• Estudia in vitro a mustra ku THC i CBD por indusí apoptosis (muerte di sel programá), inhibí proliferashon, i redukí angiogénesis (formashon di basonan di sanger ku ta alimentá tumor) den sertan línea di sel di kansèr .
• Estudia di modelo animal a mustra algun inhibishon di kresementu di tumor den ratón i ratón tratá ku kanabinoid .
• E hamentu nan aki a jenere interés siéntifiko legítimo i investigashon kontinuá.

Kiko e literatura prekliniko no mustra

• E hamentu nan aki no a tradusí den kura kansèr humanu prová. E lèns entre resultadó in vitro òf animal i outcome kliniko human ta vasto, ben dokumentá door di henter investigashon di onkoloxía, i ta partikularmente relevante aki.
• Ningun trial kliniko humanu a mustra ku RSO òf kualkier preparashon di asietá di kanábishiku por kura kansèr.
• Varios trial humanu chiki di kanabinoid en konteksto di kansèr (partikularmente glioblastoma) a worde kondusí, pero nan a keda eksploratorio, chiki, i no produkí e tipo di resultado ku lo sopòrta reklamashonnan di kura kansèr .

Posishonnan institushonal

• U.S. National Cancer Institute (NCI) a konosé ku kanabinoid a worde studiá pa potensial efekto antikanker den laboratorio i modelo animal pero no endosa kanábishiku òf asietá di kanábishiku komo trata di kansèr .
• U.S. Food and Drug Administration (FDA) no a aprobá kualkier producto di planta kanábishiku pa trata di kansèr. Úniko produkto di kanabinoid aproba dor di FDA ta pa otro indikashon spesífiko: Epidiolex (CBD) pa sertan desorden di konvulsión i dronabinol/nabilone (análogo sintétiko di THC) pa nausea i vomiting relashoná ku kimoterapia i pérdida di peso relashoná ku VIH/SIDA [1].
• Health Canada nunka a aprobá RSO òf asietá di kanábishiku komo kura kansèr.
• NCCIH deskirí eksplísitamente ku e evidensia kanabinoid mas fuerte ta pa epilepsia raro, nausea i vomiting relashoná ku kimoterapia, i indikashonnan di apetito òf pérdida di peso asosiá ku VIH/SIDA—no kura kansèr [1].

Pa residentenan di Kòrsou ku ta navigá konversashonnan ku onkologo na SEHOS òr ta konsiderá enfoke integrativo hunto ku trata konvensional na institushon manera Instituto Oncológico Nacional, e klaridat institushonal aki ta vital. E posishonnan aki ta representá konsenso di autoridatnan médiko, no marketing di industria di kanábishiku.

Kiko Simpson a hònri korekto

Simpson a trese atenshon na kanabinoid komo un area serio di investigashon biomédiko na un momento ku mayoria di mundu tabata ignora òf aktivamente suprimí henter e konversashon aki. Su abogashí—sea inpresiso siéntifikamente—a yudá krea e kondishonan polítiko, kultural, i soshal pa industria legal di kanábishiku i e infrastrukturnan di investigashon kanabinoid ku ta eksistí awendia. É tabata entre e promer na trese asietá konesentrá di kanábishiku na konosementu públiko amplio, i e tèrmino RSO mesun ta keda e nomber mas rekonesé pa ekstrak kanábishiku full-spectrum den bokabulario di konsumidor. Kontribushonnan aki ta real i histórikamente significante.

Kiko él a sobrereklamá

E salto for di signal prekliniko pa kura kansèr no tabata apoyá pa evidensia humanu ora Simpson a has’é, i no ta apoyá awor. Anima pashientenan—partikularmente pashientenan di kansèr—pa dependé di RSO komo trata primario en lugar di terápianan onkológiko prová (kirugía, radioterapia, kimoterapia, inmunoterapia) trese daño genuino potensial. Trata atras òf no duna trata pa kanser tratable ta un preokupashon dokumentá den literatura di medicina alternativa. Siguridat absoluto di Simpson tokante reklamashonnan di kura, aunke komprensibel for di perspektiva di experiensia personal, a sobrepasá lo ku e evidensia por a sopòrta y aun ta sobrepasá é awendia.

Legado di Rick Simpson i evolusyon di RSO moderno

E tèrmino RSO awor ta usa amplia—i hopi biaha floho—den industria legal di kanábishiku. Hopi producto etiketá komo RSO tin poco resemblansa ku kiko Simpson originalmente a hasi. Den dispensario awendia, RSO por referí na kualkier ekstrak kanábishiku full-spectrum bendí na fòrma di syringe, sin importá método di ekstrashon, perfil di kanabinoid, kontenido di terpeno, òf uso intendí. E tèrmino a bira jenérico .

Simpson mesun a keda kritiko di producto komersial ku ta uza e nomber RSO mientras nan ta sparté grandemente for di su método i filosofía original. É a públikamente bisa ku hopi producto bendí komo RSO no kumpli ku su standardnan i ku komersialisashon di asietá di kanábishiku ta kontradisí su intencion original. Modelo di Simpson tabata eksplísitamente anti-komersial—é a duná e asietá for free i a instigá otro pa hasi nan mes mesora di komprá for di kompañianan .

E tenshon filosófiko aki ta worde di konosementu. Simpson tabata kere den un modelo has’é-bo-mes, akseso for free unda kualkier por kosechá kanábishiku, ekstrá e asietá, i trata nan mes òf nan ser keridunan sin intermediario korporativo òf guvernamental. Industria moderna di kanábishiku a hasi algo diferente: a komersialisá, estandarisá, i regulá kiko Simpson a distribuí for free. Si e evolusyon aki ta representá un mehora (door di kontrol kalidat, test lab, i presishon di dosis) òf un traishon (door di ekstrakshon di ganansia i gatekeeping regulatório) depende di perspektiva di hende, i komunidad di kanábishiku ta divdidí riba e pregunt aki.

Lo ku no ta diskutibel ta ku RSO moderno a evoluciona substansialmente for di su orígen, i e kambionan aki ta direktamente relevante na e fórmulanan den e dokumento aki.

RSO tradisional vs RSO formulá moderno

E tabel siguiente ta resumí e diferensia klave entre RSO tradisional manera Simpson a definí é i e enfoke formulá moderno uza den producto di OilWell.

Dimenshon	RSO Tradisional	RSO Formulá OilWell
Materia fuente	Single strain altu-THC índika	Mix di multi-kanabinoid for di multiple fuente
Método di ekstrashon	Nafta òf alcohol isopropyl	Método moderno ku etanol di grado alimentario òf CO₂
Perfil di kanabinoid	Dominá di THC, no kontrolá	Siète kanabinoid definí na proporcion spesífiko
Kontenido di terpeno	Destruí dor di proseso di kalor haltu	Terpeno bibo na 5% ku perfil spesífiko di siète terpeno
Estandardisashon	Ningun—kada produkshon diferente	Test lab ku meta spesífiko mg/mL
Test lab	No disponibel òf ehecutá	Panel kompleto di test
Solvent residual	Risko significante ku nafta	Kontrolá i test
Presishon di dosis	Aproksimadamente, basá riba syringe	Medí pa mL ku kontenido kanabinoid konosé (553 mg/mL)
Fòrmanan di producto	Solamente un asietá dik	Asietá sublingual i cartridge di vape ku fórmula spesífiko pa kada formato
Preservashon di THCa	No—deskarboxilá kompletamente dor di kalor	Si—THCa inkluí komo ingrediënt separá na 1,500 mg
Enfoke di evidensia	Anekdótiko, testigu personal	Basá riba investigashon, peso di evidensia

Pa kiko fórmula di OilWell ta divèrgi for di RSO tradisional

Fórmulanan di OilWell no ta RSO tradisional. Nan ta informá pa tradishon di RSO pero sparté for di dje en varios manera deliberate, motivá pa evidensia:

• Enfoke multi-kanabinoid. RSO tradisional tabata dependé di kualkier single strain ku e hacedor a kosechà òr fuente. Fórmula di OilWell ta intensionalmente inkluí siète kanabinoid—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, i CBC—pasobra literatura di entourage-effect sugeri benefisio potensial for di diversidat di kanabinoid, aunke prueba kliniko robusto di sinerhia total di fórmula ta limitá [20][29].

• Preservashon i adishon di terpeno. RSO tradisional tabata esensialmente no tin kontenido terpeno debi na destrukshon di solvent i kalor. OilWell ta inkluí terpeno bibo na 5% ku un perfil spesífiko di siète terpeno—limonene, myrcene, caryophyllene, pinene, linalool, humulene, i terpinolene—pasobra bioaktividat di terpeno ta plausible i apoyá riba nivel prekliniko, aunke konfirmashon kliniko humanu pa efekto spesífiko di terpeno di kanábishiku ta keda desaroyando [20][21][23][24][25][26][27][28][29].

• THCa komo ingrediënt separá. RSO tradisional a deskarboxilá tur kos, konvirtí tur THCa den delta-9 THC. Fórmula sublingual di OilWell ta inkluí THCa na 1,500 mg komo un ingrediënt distinto, preservando e prekursor ácido pasobra e perfil di evidensia di THCa den seksion GENERAL KNOWLEDGE nota ku THCa mesun no produkí e efekto psikoaktivo asosiá ku THC pero ku su interpretashon depende di ruta, temperatura, prosesamiento, i almacenashon—pasobra THCa por konvertí na THC bao kalentura òr bèrdad di tempu [12].

• Redukshon di dominansia di delta-9 THC. RSO tradisional tabata abrumadoramente delta-9 THC—kasi 60 te 90 porsiento di kontenido total di kanabinoid. Fórmula sublingual di OilWell uza delta-9 THC solamente na 90 mg mientras ta inkorporá delta-8 THC na 6,000 mg i distribuí e kontenido restante di kanabinoid entre CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), i CBC (750 mg)—un perfil farmakológiko kompletamente diferente.

• Innovashon di fòrma di producto. Simpson a vizualisá solamente un formato: un asietá oral administrá for di un syringe. OilWell ofresé tanto un asietá sublingual di 30 mL ku un cartridge di vape di 1 gram, kada ku su propio fórmula spesífiko pa formato, rekonosé ku diferente ruta di entrega tin diferente perfil farmacokinétiko [14].

Siguridat di solvent i evolusyon di ekstrashon

Produkshon tradisional di RSO a usa nafta òf alcohol isopropyl—ningun di nan dos no ta solvent di grado alimentario. Nafta ta un mezcla kompleho di hidrokarburo di petrolio ku por kontené benzene, toluene, xylene, i otro komponé klasifiká komo tóksiko òf karsinogéniko. Purga inkompleto di solvent—ku ta difísil pa verifiká sin ekipo siéntifiko analítiko—ta laga residu potensialmente dañoso den e asietá finish.

Ekstrashon moderno di kanábishiku abrumadoramente uza etanol di grado alimentario òf dwein di karbon superkritiko (CO₂). E método aki ta permití removeshon di mas kompleto di solvent, i e producto finish por wordu test pa solvent residual uza método analítiko validá manera headspace gas chromatography. Esaki ta un di e mehoramentnan mas direkto ku industria regulá di kanábishiku moderna a hasi riba modelo di produkshon tradisional di RSO.

E evolusyon aki ta konektá direktamente ku diskushon di kalidat di producto den seksion GENERAL KNOWLEDGE di e dokumento aki, ku ta enfatisa ku kalidat di producto ta importá tanto komo identidat di molékula i ku inkoréksion di etket, kontaminashon, subproducto di síntesis, i variabilidat di dosis ta afectá materialmente interpretashon den producto real [1][10][11][14].

Pregunta di deskarboxilashon

RSO tradisional a wordu deskarboxilá kompletamente. E kalor involví den evaporá solvent for di e rice cooker—tipikamente mantené na òr serka di punto di ebulishon di e solvent, ku pa nafta ta aproximadamente 60 te 80 grado Celsius i pa alcohol isopropyl aproximadamente 82 grado Celsius—tabata sufisiente pa konvertí esensialmente tur THCa den ekstrak den delta-9 THC. E konvershon aki ta termodinámicamente favosé i ta progresá fácilmente na e temperaturanan aki door di e durashon involví den evaporashon di solvent.

Komo resulta, e kanabinoidnan ácido ku ta abundá den materia planta kanábishiku raw—inkluyendo THCa, CBDa, CBGa, i otro—a worde pèrdè komo komponé distinto den RSO tradisional. E asietá finish tabata un producto deskarboxilá, aktiva dominá pa kanabinoid neutral (no ácido).

Fórmula sublingual di OilWell ta deliberatemente preservá THCa na 1,500 mg komo un ingrediënt separá. Esaki ta un chòis formulashon intensional informá pa e perfil di evidensia di THCa den seksion GENERAL KNOWLEDGE, ku nota ku THCa mesun no produkí e efekto psikoaktivo asosiá ku THC pero ku su interpretashon depende di ruta, temperatura, prosesamiento, i almacenashon—pasobra THCa por konvertí na THC bao kalentura òr bèrdad di tempu [12].

Perdida di terpeno den RSO tradisional

Terpeno ta komponé aromátiko volátil ku punto di ebulishon relativamente abou. Mayoria di terpeno di kanábishiku kuminsá pa volatilizá na temperaturanan entre 21 i 157 grado Celsius, ku hopi di e terpeno mas abundante—inkluyendo myrcene, limonene, i pinene—tin punto di ebulishon bao 180 grado Celsius. E proseso di produkshon tradisional di RSO a destruí terpeno den dos manera: promé, dor di disolvé nan den e laba ku solvent hunto ku kanabinoid; i despues, dor di evaporé nan durante e fase di removeshon di solvent ku kalor haltu.

Eso a signifiká ku RSO tradisional tabata esensialmente un producto di solamente kanabinoid, a pesar di derivá for di un planta ríkí di terpeno. Kualkier komponé aromátiko, di sabor, òf potensialmente bioaktivo terpeno ku e kanábishiku fuente a kontené a worde pèrdè den produkshon.

Fórmula di OilWell ta spesifiká terpeno bibo na 5% ku un perfil definí di siète terpeno: limonene, myrcene, caryophyllene, pinene, linalool, humulene, i terpinolene. Kada terpeno aki tin su mesun perfil di evidensia diskutí den seksion GENERAL KNOWLEDGE. Literatura di entourage-effect [20][29] ta provey e framework teóriko pa kiko preservá i inkluí terpeno hunto ku kanabinoid por ta relevante farmakológicamente, aunke prueba kliniko robusto humanu di efekto spesífiko di entourage pa kanábishiku ta keda desaroyando.

Standard di evidensia den e tempu i awor

Rick Simpson a opera den un époka pro-legalisashon, pre-test-lab. Ora él a kuminsá hasi i distribuí asietá na kaminda di 2000nan, kanábishiku tabata illegal na Canada i henter mayoria di mundu. No tabatin un marco regulatório pa producto di kanábishiku, nin infrastrukturnan di test estandarizá, no tabatin kaminda legal pa investigashon kliniko riba protocol di asietá di kanábishiku, i no tabatin revista revisá pa par dediká na terapéutika kanabinoid. E underworld di kanábishiku tabata e úniko punto di akseso, i experiensia personal tabata e moneda di evidensia primario.

Método di Simpson a reflektá restricción di e époka aki. Su evidensia tabata anekdótiko. Su produkshon tabata no estandarizá. Su reklamashonnan tabata no testá den kualkier sentido formal. Eso no ta faya moral nesesariamente—ta un deskripshon di e ambiente unda él a opera.

E dokumento aki ta hunga un rol fundamentalmente diferente. Sekshon GENERAL KNOWLEDGE ta apliká un jerarquía formal di evidensia: evidensia kliniko humanu promé, despues revisyon sistemátiko i meta-análisis, despues resumen institushonal, despues literatura prekliniko i mekanístiko [1]-[29]. Kada reklamashon di nivel komponé ta konektá na fuente revisá pa par spesífiko ku forsa di evidensia klaramente etiquetá. E intencion ta honra e orígen históriko di RSO mientras ta komprometé ku standardnan di siansa moderna di kanabinoid. Kaminda Simpson a dependé di testigu personal, e dokumento aki ta dependé di literatura publiká i fuente institushonal.

Protocol di Simpson vs. konsiderashonnan di dosis moderno

Protocol di 60 gram/90 dia di Simpson tabata diseñá basá riba un ekstrak krudo, single-strain, dominá di THC sin potensia estandarizá. Un komparashon direkto entre rekomendashonnan di dosis di Simpson i dosis ku un fórmula moderna, estandarizá, multi-kanabinoid no ta direkto—producto nan ta fundamentalmente diferente.

Varios diferensia klave mustra pa kiko:

• Konsentrashon di kanabinoid. Fórmula sublingual di OilWell ta entregá 553 mg di kanabinoid aktivo total pa mL entre siète komponen definí. Potensia di RSO tradisional tabata deskonosé i variabel.
• Proporcion di kanabinoid. Asietá di Simpson tabata aproximadamente 60 te 90 porsiento delta-9 THC. Fórmula di OilWell ta distribuí 16,590 mg di kanabinoid total entre CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), i CBC (750 mg)—un perfil farmakológiko kompletamente diferente.
• Presensia di terpeno. Asietá di Simpson no tabatin terpeno. Fórmula di OilWell ta inkluí terpeno bibo na 5%, ku por influensia absorpshon, efekto, i tolerabilidat.
• Eksposhon delta-9 THC. Protocol di Simpson na dosis piko a entregá aproximadamente 600 te 900 mg di delta-9 THC pa dia. Fórmula sublingual di OilWell ta kontené solamente 90 mg di delta-9 THC den henter e boter di 30 mL (3 mg pa mL), hasiendo e eksposhon delta-9 THC pa dosis drástikamente mas abou.

Guia di dosis futuro pa producto di OilWell mester wordu desaroyá independientemente di protocol di Simpson, informá pa evidensia pa komponen dje den seksion GENERAL KNOWLEDGE i pa prinsipionan responsabel di titrashon ku ta konta ku perfil siuridat di kada kanabinoid individual. E seksion aki no ta provey rekomendashonnan di dosis spesífiko—e trabou aki lo rekerí su proseso di desaroyo propiu i mester inkluí e konsiderashonnan di siuridat dokumentá henter e dokumento aki.

Referensianan pa e seksion aki

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story [fílm di dokumentario]. 2005. Distribuí via phoenixtears.ca i platformnan online.

RS3. Simpson R. Instrukshonnan i informashon di dosis publiká riba phoenixtears.ca. Varias fecha. Aksesá Mei 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Aktualisá 2024. Disponibel na: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

TOKANTE OILWELL CANNABIS I FÓRMULA OILWELL RSO

Orígen di OilWell Cannabis

OilWell Cannabis a worde fundá dor di Colin Valencia na Houston, Texas. Mientras nos base ta Montrose, Houston, nos misión traspasa frontera. Nos a krea un línia di producto ku honra e espíritu grassroots di visión original di Rick Simpson mientras ta solushona problema di siguridat, kalidat, i legal. Pa residentenan di Kòrsou—un lugar unda akseso na kuido médiko por ta limitá, unda e klima tropical aklara degradashon di producto, i unda actitúd cultural tokante kanábishiku ta evolucioná—entendé e diferensianan aki no ta solamente útil. Ta esensial.

Colin a krese na McAllen, Texas—djedé ku Reynosa, Tamaulipas, México. Area McAllen-Reynosa, konosí komo Borderplex, ta uno di regionnan mas desafiá ekonómicamente i peligroso a lo largu di frontera Merikano-Mexicano. McAllen ta un sudad di kontraste—kultura bibrante i sektor di venta di mayoria krese, pero afektá fondo pa pobresa i oportunidat limitá fòrki di industria di venta i sûit. Reynosa, otro banda, ta un hub industrial plagá di violensia i aktividat di kartel, hasiendo un ambiente duru pa kualkier hende ku ta krese aya.

Kinseñes di Colin na McAllen a keda marká ku eksposhon tanto na oportunidatnan komo na desafionan di bida a lo largu di frontera. Tempran, él a aprendé pa hasi trabou di ínterim, asumiendo trabou riskante transportando artíkulonan krús frontera pa varios grupo. E experiensia tempran aki a exponé é komplexidatnan i peligronan di bida den e region aki. Hopi di su wowo bon amigo a worde mata òr ta den prishon pasobra di e peligronan asosiá. É a enfrentá tur forma di violensia imajinable, tanto na kaya ku krús frontera. Na diesiséis, un manera òr otro, mester a laga kas pa semper.

A pesar di e peligronan, Colin no a kai den e kaminda mas skur disponibel, manera bende substansiah mas duru. Envez, él a fokusá riba kanábishiku, mirando komo un alternativa mas seguro i benefisioso. É a krese den mundu tradishonal di kanábishiku prome di legalisashon, aprendé e planta intimamente mientras operando den skur. Dor di tempu, él a transishon for di eses biahanan tempran riskante pa krea un negoshi legal, legítimo den un industria ku él kere den dje.

Colin despues a bira un inginiero software formalmente entrená i a hasi trabou di desaroyo custom pa Baylor College of Medicine, uno di e institushon médiko mas prestigioso den Texas Medical Center. E kombinashon—konosementu profundo di planta kanábishiku mas presishon téknika di nivel médiko—eventualmente a definí enfoke di OilWell.

Storia di Bentley: for di paralisá te hunga

Storia di origen di e kompañía ta kuminsá ku un perro nombrá Bentley. Bentley tabata mas ku solamente un mascota—tabata un miembro di família, un kompañero ku a para ku Colin duranti e tempnan mas duru. Ora Bentley a kayer malu serio, veterinario a entregá e veredikto ku ningún dueño di mascota ke tende: eútanasia tabata ser humano. Bentley a worde paralisá na su pia trasero. Nan a bisa ku e medikashonnan pa dolor lo destruí su órgano interno, hasié sufrí mas dolor i sufrimentu. E dikshon tabata painful decline prolongá òr muerte inmediatamente.

Pero drenta Bentley no tabata un opshon. Colin ya a enfrentá muchu pérdida i a mira muchu sufrimento den su bida. Bentley tabata un luchador, eksaktamente ku él, i Colin no tabata listu pa lagaé bai. Na un buskada desesperá di alternativa, él a topa ku propiedatnan kura di CBD—dor di un preguntashon ku a kambia tur kos.

Un trahadó di rescate ku kurason bon nombrá Jessica a puntra Colin: “Bo a move kuantu ton di weed i nunka a tende tokante CBD?”

Colin tabatin experiensia ku kanábishiku—pero tabata rekreativo. Hasi hòchi. Nunka a investigá e aplikashonnan terapéutiko i médiko. Preguntashon di Jessica a eksponé un punto siega ku lo bira un misión.

Determiná pa salva Bentley, Colin a aprendé pa krea pasta dora di CBD—un fórmula kanabinoid spesialisá pa mascota. No tabata un kura, pero tabata un salvavidas—i tabata speransa. Y e speransa aki a entregá algo ku médika veterinario a bisa ta imposibel: Bentley a para. É a kaminá bai na Colin i a trese su bal pa hunga. Tabata un milagro. For di paralisá i enfrentando eútanasia te na traé su bal pa hunga. Esey no tabata efekto placebo—perro no ta respondé placebo. Eso tabata medicina kanabinoid ta traha kos ku farmaséutika no por.

Bentley a biba otro dies aña, pasando naturalmente na edad di binti. Durante e dies aña aki, Colin a desaroyá fórmula kanabiniku spesial pa kada kondishon relashoná ku edad ku Bentley a enfrentá. Neurodegenerashon a harié entendé propiedat neuroprotektivo di CBG i agonismo PPARγ di THCa pa protekshon di sel di berein. Demensia a harié entendé rol di CBC en neurogénesis. Gloukoma a harié entendé agonismo CB1 di THC pa redukshon di presion intraocular. Artrítis debilitante a harié é desaroyá enfoke anti-inflamatorio multi-kaminda uza CBD, CBG, THCa, i beta-caryophyllene trahando door di sistema receptor diferente simultanéamente.

Kanabinoid single no tabata sufisiente. Kondishonan evoluí di Bentley a rekerí sinerhia multi-kanabinoid. CBD solamente no por a adresa neurodegenerashon i demensia i gloukoma i artrítis simultanéamente. Kanabinoid menor manera CBG, CBN, i CBC a bira krítiko mientras Bentley a bèrdad di edad. Presishon farmaséutika tabata importa—bida di Bentley a dependé di presishon di fórmula, no suposhon.

Storia di Bentley a bira entrada di Colin den mundu di kanábishiku mas allo di solamente hasi hòchi. A bira un misón pa krea solushonnan real ku yuda alivia dolor i sufrimento, no solamente pa mascota pero pa hende tambe. Storia di Bentley ta fundashon di OilWell Cannabis, hasiendo su kompromisù ku kalidat, innovashon, i kuido kompasivo.

Bataya personal di Colin: PTSD, adikshon benzo, i kreashon di Peace

Colin tambe konose dependensia farmaséutika personalmente. É a lucha ku PTSD i adikshon benzodiazepina. Ora él a desidí pa laga Xanax, él a has’é cold turkey—un hazaña ku ta notoriamente difísil i peligroso—uza e konosementu kanabinoid ku él a desaroyá mantené Bentley biba. E fórmula di Peace Gummies ku a bira un producto di OilWell a worde krea durante eksperimento di mantanè mientras ta luchando ku síntoma di retiro benzo. Pa sigurá alivio rápido, OilWell tambe ofresé e fórmula di Peace Gummies na forma di vape, ku Colin personalmente uza pa manejá su insomnio i PTSD severo. Esey no ta konosementu teóriko. Colin a biba lo ku pashientenan di RSO ta bivi: desesperashon pa alivio, farmaséutika frakasá, deskubrimento ku kanabinoidnan traha ku pastòl no por.

Pa residentenan di Kòrsou ku ta trahando ku konsekuensianan mental di huracán, inseguridat ekonómiko, òr trauma personal, e experiensia personal aki ta importa. Nos ta entendé ku rekursnan di salú mental riba isla por ta limitá, i ku estigma tokante tanto enfermedat mental komo úso di kanábishiku ta keda real. Nos enfoke ta base riba experiensia bibu, no marketing korporativo.

Konstruyendo pa nesesidatnan real di hende

Den tempu, benefisio terapéutiko di kanábishiku ku Colin prome a deskubrí door di su isfuerzo pa salva Bentley a bira núkleo di su trabou. É a desaroyá fórmula ku dokternan uza pa kondishon manera Crohn, IBS, ulsera kolitis, PTSD, adikshon benzo, i insomnio. Su fokus a keda semper riba hasi kanábishiku aksesibel i efektivo pa tur hende, inkluyendo vegan, diabetes, i esnan ku nesesidatnan spesífiko di salú.

ABC13 KTRK Houston—funte di notisia número un di Houston—a presentá Colin i OilWell Cannabis den siete segmento di notisia komprehensivo ku ta sosténan 2019 te 2023, kubrí ley di marihuana Texas, analís legal Delta-8, liderasho di salú komunitario COVID-19, reforma di hustisia kriminal, i pionernan di negoshi kanábishiku. Colin a worde selektá ripitidamente komo e eksperto primario di industria pa kuverdura di polítika kanábishiku i producto na kuat sudad mas grandi di Merika.

Kita di Colin for di e promer ABC13 feature na September 2019 kaptura filosofía di OilWell: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Operashon aktual: Hecho na Houston, aksesibel globally

Awendia, OilWell Cannabis ta opera for di Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). E kompañía ta operando desti 2019, jenere aproximadamente un mion dólar den revenu anual, mantené un kalifikashon Google serka di 5.0, i ta tin licensia Texas DSHS. Producto di OilWell no ta produhí en masa—nan ta elaborá cuidadosamente ku un toke personal, for di e arte riba e paki te ku e fórmulanan pa aden. Tur arte, fórmulanan, i pakinan ta worde krea in-house na Houston, uza solamente reseta i ideanan di OilWell. Colin ta traé determinashon di Houston, rais di McAllen, i mentalidat di konstruktor na e kompañía, pero e postura ta keda simpl: hasi producto ku intenshon, respondé drechi, i nunka pretende ku kanábishiku ta korekto pa tur hende.

Pa klientenan di Kòrsou, eso ta nifiká bo ta haya un producto hasi ku mesun kuido i presishon ku nos ta duna na nos bínsidanan di Houston. Nos kontrol di kalidat, formulashon in-house, i proseso di produkshon manual no ta diluí pa shipping internashonal—nan ta fundashon di kiko nos producto nan traha.

Filosofía RSO di OilWell

RSO di OilWell no ta Rick Simpson Oil tradisional. Ta un producto formulá, multi-kanabinoid informá pa tradishon di RSO pero sparté for di dje en manera deliberate, motivá pa evidensia, diseñá pa solushona problema ku a limitá visión original di Rick Simpson.

Kuater prinsipio núkleo defini enfoke di OilWell, kada ta aliná i evolucioná e ethos original di Simpson:

1. Aksesibilidat mas ku gatekeeping. Ningun karchi médiko ta rekerí. Kualkier hende di binti-un òr mas por komprá. OilWell ta shipá henter Meriká i internashonalmente pa klientenan ku verifiká legalidat lokal. Simpson a kere ku medicina mester aksesibel pa tur hende; OilWell a krea un producto i modelo di distribushon ku ta hasa eso legalmente—inkluyendo pa residentenan di Kòrsou ku por no tin akseso dispensario lokal òr programa di kanábishiku médiko.

2. Potensia kontrolá pa pashiente. THCa ta bendí den formá ácido, no psikoaktivo. Kliente ta desidí si uzaé raw pa benefisionan no psikoaktivo òr deskarboxiláé den delta-9 THC pa potensia psikoaktivo kompleto. Simpson a kere ku pashientenan mester kontrola nan mesun medicina; OilWell a ingeniá un producto ku ta pone e kontrol aki den man di kliente door di kimika mas ku retórika. Pa residentenan di Kòrsou ku mester traha, guine, òr kuida família durante dia, eso ta nifiká bo por uza e formá raw sin impair. Pa esnan buskando forsa terapéutiko kompleto na nochi, aktivashon ta simpl i legal.

3. Fórmula open-source. OilWell ta publiká nan fórmula kompleto di RSO públikamente—kada kanabinoid, kada kantidat miligram, kada porsent—pa ku kualkier ku no por hase e producto por haña ingrediëntenan i hasi nan mesun version. E fórmulanan den seksionnan RSO Sublingual Oil i RSO Vape Cartridge di e dokumento aki ta e fórmula open-source.

E ethos aki ta un echo direkto di ethos original di Rick Simpson. Simpson a duná su asietá for free i a hanse hende kuña hasié. Nunka a paténta su método. Nunka a kobra pashientenan. OilWell a adaptá e ethos aki pa merkado moderno di kanabinoid: nos bende un producto profesionalmente manufakturá, test lab, estandarizá pa esnan ku ke é, i publiká e reseta kompleto pa esnan ku ke a hasié nan mes.

Pa residentenan di Kòrsou ku ta enfrentá desafío ekonómiko òr prefere médika DIY, e enfoke open-source aki ta revolushonario. Bo por haña kanabinoidnan derivá di hemp for di proveedornan internashonal (sigurando nan kumpli ku rekerimentu importashon di Kòrsou) i krea bo mes RSO uza nos spesifikashonnan eksakto. Nos ta provey e mapa; bo ta skohe e biahe.

Segun Colin Valencia a bisa riba ABC13 na 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

E filosofía open-source no a kuminsá ku RSO—a kuminsá ku Bentley. Rib About Us page, Colin a publiká e reseta real di pasta dora di CBD ku a salva bida di Bentley, pa ku kualkier dueño di mascota enfrentando krisis similar por a hasié nan mes:

Reseta di pasta dora di CBD pa mascota—e fórmula open-source original

Ingrediëntenan:

• 1/2 taz di polvo kurkuma orgániko
• 1 taz di awa
• 1/3 taz di manteka di koko (no refina, orgániko)
• 1 te 2 kucharadita di pimenta pret frèk (importante pa absorpshon)
• Asietá di CBD (dosis depende di tamaño i nesesidat di e mascota; konsultá ku un veterinario)

Instrukshonnan:

1. Meksa kurkuma i awa. Den un kaserola, kombiná polvo di kurkuma i awa, revolví riba kalor abou. Revolví kontinuamente te forma un pasta dik. Esaki mester tuma alrededor 7 te 10 minuut. Agregá un tiki awa mas si ta bira muchu dik.
2. Agregá manteka di koko i pimenta. Ora bo tin un pasta dik, agregá manteka di koko i pimenta pret frèk. Revolví te tur ingrediëntenan ta meksa bon.
3. Frío i almacená. Laga e pasta fría, despues transferí pa un frasko ku tapa. Almacená den refriherdor pa te dos siman.
4. Dosis. Agregá un kantidat chikí di asietá di CBD na e pasta prome di dunáé na e mascota, adjustá e dosis basá riba su peso i nesesidat di salú. Kuminsá ku dosis abou i graduálmente aumentá segun nesesidat.

Sugerensia di sirbi: Meksá un kantidat chikí di e pasta dora ku kome di e mascota un òr dos biaha pa dia. Monitor e mascota pa kualkier kambio i konsultá ku un veterinario si tin preokupashon. Konsultá semper ku un veterinario prome di kuminsá kualkier regimen di suplemento nobo pa un mascota.

E reseta aki—publiká for free, añanan prome ku e fórmula di RSO a wordu open-source—mustra ku e patrón ta konsistente. Colin a duná e fórmula ku a salva Bentley prome ku el a duná e fórmula diseñá pa hende. E ethos open-source no a kuminsá ku RSO—a kuminsá ku Bentley. E ethos aki no ta estrategia di marketing. Ta e komportament fundashonal di e kompañía.

Dikshon di deskarboxilashon—potensia kontrolá pa pashiente

RSO tradisional a wordu deskarboxilá kompletamente siempre. E kalor di evapora solvent for di e rice cooker—tipikamente mantené na òr kerca di punto di ebulishon di e solvent, ku pa nafta ta aproximadamente 60 te 80 grado Celsius i pa alcohol isopropyl aproximadamente 82 grado Celsius—tabata sufisiente pa konvertí esensialmente tur THCa den ekstrak den delta-9 THC. E konvershon aki ta favosé termodinámicamente i ta progresá fácilmente na e temperaturanan aki door di e durashon involví den evaporashon di solvent.

Komu resultado, e kanabinoidnan ácidu ku ta abundá den materia planta kanábishiku raw—inkluyendo THCa, CBDa, CBGa, i otro—a worde pèrdè komo komponé distinto den RSO tradisional. E asietá finish tabata un producto deskarboxilá, aktiva dominá pa kanabinoid neutral (no ácido).

Fórmula sublingual di OilWell ta deliberatemente preservá THCa na 1,500 mg komo un ingrediënt separá. Esey ta krea tres opshón di uso distinto pa kliente:

Opshon 1—Raw, sin kalor. Tur 1,500 mg ta keda komo THCa—kompletamente no psikoaktivo. E perfil di evidensia di THCa den seksion GENERAL KNOWLEDGE ta deskribí potensial aktividad anti-inflamatorio via inhibishon di COX-2 i potensial neuroprotektivo via agonismo PPARγ [12]. E opshon aki ta kompatibel ku trabou, guine, i úso di dia sin impairment psikoaktivo. Pa residentenan di Kòrsou ku ta comutá diariamente for di Jan Thiel pa Willemstad, operá ekipo pesante den sektor di refinería òr simplemester nesesitá keda kla di kabes mientras ta kuida família, esaki ta un game-changer.

Opshon 2—Aktivá kompletamente, deskarboxilashon na kas. Kalentá e asietá na 260°F (125°C) pa 45 te 60 minuut den un kontenedor di glas segur pa forno konvertí 1,500 mg di THCa na aproximadamente 1,315 mg di delta-9 THC. Kombiná ku e 90 mg di delta-9 THC eksistente na fórmula, esaki ta produkí aproximadamente 1,405 mg di delta-9 THC—hasiendo e producto tin potensia psikoaktivo komparabel ku RSO tradisional illegal, 100% legal, pasobra deskarboxilashon ta okoré na desishon di kliente despues di kompra. Kliente tamen por transferí un porshon kontrolá di e asietá for di e boter original pa un segundo kontenedor di glas segur pa forno, deskarboxilá solamente lo ku nan ke uza i preservá e resto den formá THCa raw.

Opshon 3—Vape, deskarboxilashon automatico. RSO Vape Cartridge ta vaporizá na 400 te 450°F, ku instantáneamente konvertí THCa den delta-9 THC ku kada inhalashon. Kada bocada ta entregá kanabinoid deskarboxilá frèt-frèt. Esaki ta e método di entrega RSO mas rápido disponibel—ideal pa dolor breakthrough agudo, atake di pániko, òr nausea ku ta ataké de repente.

E kimika di konvershon: THCa tin un peso molekular di 358.47 g/mol. E proporcion di konvershon ta aproximadamente 1 mg THCa = 0.877 mg delta-9 THC despues di deskarboxilashon, reflehando pèrdida di un molékula di CO₂ durante reakshon.

E diseño aki ta pone e dikshon di potensia totalmente den man di kliente—alineá ku prinsipio di Rick Simpson ku pashientenan mester kontrola nan mesun medicina, pero implementando e prinsipio aki door di kimika di producto real mas ku un enfoke one-size-fits-all. Pa residentenan di Kòrsou, esaki ta nifiká un kompra ta sirvi ku múltiple nesesidatnan durante diferente momentu di dia i diferente situashon.

Produkshon sin solvent

RSO di OilWell no ta un producto di ekstrashon en sentido tradishonal. Ta un mezcla formulá di destiladonan i isoladonan individual di kanabinoid kombiná na proporcion spesífiko den un ambiente di produkshon kontrolá. Ningun nafta. Ningun alcohol isopropyl. Ningun butano. Ningun solvent di ekstrashon ta presente den e producto finish.

E enfoke aki eliminá risko di solvent residual ku ta uno di e preokupashonnan di siguridat mas significante ku produkshon tradisional di RSO, manera diskutí den seksion tokante Rick Simpson.

E producto uza asietá MCT orgániko (trigliserida kadena mediano) komo base di transportador. Asietá MCT ta un transportador lipídiko di grado alimentario ku facilita absorpshon di kanabinoid door di teido sublingual i ta provey un perfil di sabor neutral—un mehora significante konpará ku konsistensia komo alquitrán i olor residual di solvent di RSO tradisional. Na klima tropical di Kòrsou, asietá MCT tambe ofresé mas estabilidat ku hopi otro transportador, resistiendo ransididat den kalor i humedidat.

Test di tercer parti kubre potensia kanabinoid, perfil di terpeno, i panel di siuridat inkluyendo pesticid, metalnan pesante, solvent residual, i kontaminante mikrobiano. Certificate di Análisis (COA) ta disponibel riba petishon i akesibel via sitio web di OilWell. Pa klientenan di Kòrsou, nos ta inkluí dokumentashon kompleto di COA ku kada envio internashonal pa sigurá clearance di aña i bo pas.

Portfolio mas amplio di producto di OilWell

For di RSO, OilWell Cannabis ta produhí un rango di producto kanabinoid, kada desaroyá for di konosementu di formulashon ku Colin a konstruí durante diez aña di biahe di Bentley i su mesun experiensia ku PTSD i retiro benzo.

Asshole Peach — Producto mas popular di OilWell. Asshole Peach ta un experiensia cuidadosamente formulá diseñá pa provey un sensashon euforiko, di durashon largu. Partikularmente ta gustá pa veteranu pa su habilidat pa aliviá dolor i síntoma di PTSD sin ta muy agresivo. Pa komunidat di veteranu di Kòrsou—sea for di servisio militar Hulandes, despiegue NATO, òr forsa di seguridat lokal—e producto aki ofresé un enfoke di destinashon pa síntoma relashoná ku trauma.

Peace Gummies — Desaroyá direk for di mesun experiensia di Colin ku PTSD i adikshon benzodiazepina. Peace Gummies a yudé é laga Xanax cold turkey. E fórmula tambe ta disponibel na forma di vape pa alivio rápido—Colin personalmente uza e vape pa manejá su insomnio i PTSD severo kontinuamente.

Kreashonnan custom — OilWell ofresé producto custom hasi riba petishon spesífiko di klientenan individual. Sea si ta involví proporcion spesífiko di kanabinoid, formato di entrega partikular, òr fórmula pa sirkunstansia spesial di salú, OilWell ta diseña producto di destinashon riba petishon. Eso ta inkluyendo fórmula pa vegan, diabetes, i esnan ku nesesidat dietétiko òr di salú spesífiko. Pa residentenan di Kòrsou ku diabetes (un kondishon ku ta afectá hopi den Karibe debi na faktor dietétiko), opshonnán sin sukè aki ta partikularmente relevante.

Dos formato di producto

OilWell ta ofresé e fórmula RSO den dos formato di entrega, kada diseñá pa kaso di uso diferente i perfil farmacokinétiko diferente.

RSO Sublingual Oil — $129.99

• Boter di 30 mL (1 fl oz)
• 16,590 mg kanabinoid total (553 mg pa mL)
• Siète kanabinoid: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Terpeno bibo na 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Base: asietá MCT orgániko
• Dropper graduá pa dosis presiso en inkremento di 0.1 mL
• Inicio: 15-45 minuut (absorpshon sublingual door di mucosa oral)
• Efekto pico: 1-2 ora
• Durashon: 4-6 ora
• Bio-disponibilidat: 13-19% (ruta sublingual partiamente evité metabolismo di primer pasada den higado)
• Aproximadamente 40-60 dosis pa boter dependiendo di tamaño di serving

RSO Vape Cartridge — $49.99

• Cartridge di 1 gram
• 900+ mg kanabinoid total
• Mesun proporcion di siète kanabinoid manera e fórmula sublingual
• Terpeno bibo na 5%+
• Kompatibilidat batería universal 510-thread
• Inicio: 1-2 minuut (metodo di entrega mas rápido)
• Efekto pico: 10-15 minuut
• Durashon: 2-4 ora
• Bio-disponibilidat: 10-35% (variabel, depende di téknika inhalashon)
• Deskarboxilashon automatico di THCa na temperatura di vape (400-450°F)

Guía Kompleto di RSO — Guía kompleto di producto di OilWell ku siansia, analís kompetitivo, protocol, i informashon di oorden.

Ora di uza kada formato

Kaso di Uso	Formato Rekomendá	Razonamento
Alivio rápido (dolor agudo, nausea, pániko)	Vape	Inicio 1-2 minuut
Alivio sostenido (dolor kroniko, drumi)	Sublingual	Durashon 4-6 ora
Bio-disponibilidat máksimo	Sublingual	Absorpshon 13-19%
Portabilidat i diskreshon	Vape	Kompakto, no rekerí mesurashon
Kontrol di dosis presiso	Sublingual	Dropper graduá en inkremento di 0.1 mL
Úso di dia no psikoaktivo	Sublingual (raw, sin kalor)	THCa keda inaktivo, cero impairment
Úso di nochi psikoaktivo	Sublingual (deskarboxilá) òr Vape	THCa aktiva + delta-8 THC

Komparashon kompetitivo—OilWell RSO vs alternativa

E tabelan siguiente ta presentá komparashon faktual entre fórmula RSO di OilWell i otro producto RSO disponibel riba merkado. E komparashonnan aki ta basá riba spesifikashonnan di producto públikamente disponibel i ta presentá pa konteksto informativo.

OilWell RSO vs. RSO dispensario TCUP Texas (p.e., Texas Original)

Dimenshon	RSO Dispensario TCUP	RSO OilWell
Perfil kanabinoid	Solamente THC (aprox. 420 mg THC pa 0.5 g syringe)	7 kanabinoid: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
Kontenido CBG	0 mg	3,000 mg
Kontenido CBN	0 mg	750 mg
Kontenido CBC	0 mg	750 mg
Potensia kontrolá pa pashiente	No—semper psikoaktivo	Si—THCa no psikoaktivo te ku kalentá dor di kliente
Rekerimentu di akseso	Karchi médiko TCUP ku kondishon kualifikando	Edat 21+ solamente, ningun karchi médiko rekerí
Kondishon kualifikando	Kansèr, PTSD, epilepsia, autismo, enfermedat terminal, ALS, MS, desorden di konvulsión, desorden neurodegenerativo inkurabel	Ningun rekerí
Entrega	Mester biaha pa lokashon físiko di dispensario	Shipá direk pa Kòrsou ku dokumentashon kompleto
Kumpreshon Farm Bill	No—programa estatal di kanábishiku médiko	Si—menos ku 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (p.e., Lazarus Naturals)

Dimenshon	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Kanabinoid total	1,000 mg	16,590 mg
Kontenido CBD	Aproximadamente 950 mg	4,500 mg
Kontenido CBG	15.5 mg	3,000 mg
Kontenido CBN	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (konvertibel na delta-9 THC)	Mínimo	1,500 mg (konvertí na aproximadamente 1,315 mg delta-9 THC)
Opsyon psikoaktivo	Ningun efekto psikoaktivo significante	Si—via deskarboxilashon di THCa i delta-8 THC
Preis aproximado	$40 te $50	$129.99

OilWell RSO vs. RSO illegal tradisional—E komparashon aki ta presentá den tabel Traditional RSO vs. modern formulated RSO den seksion TOKANTE RICK SIMPSON. Refere na e tabel aki pa komparashon kompleto di 11 dimenshon.

Konteksto di uso spesífiko pa kondishon

Disclaimer importante: E siguiente konteksto di uso ta informá door di investigashon di kanabinoid sitá den seksion GENERAL KNOWLEDGE di e dokumento aki i por rasonamentu formulashon di OilWell. Nan no ta preskripshon médiko, no ta protocol di trata aproba dor di FDA, i no ta substituto pa kuido médiko profesional. E producto aki no a worde evaluá dor di Food and Drug Administration i no ta intencioná pa diagnostiká, trata, kura, òr prevení kualkier enfermedat. Konsultá semper un provedor di kuido médiko kualifiká prome di uza producto kanabinoid, spesialmente si bo tin un kondishon médiko, ta tuma medikashon, ta boneha òr ta dando seno, òr tin kualkier preokupashon di salú. No operá vehíkulo òr maquinaria mientras ta bao influensia di kanabinoid psikoaktivo.

Nausea i sosten di apetito relashoná ku kimoterapia

• Promé kimoterapia: 0.5 te 1.0 mL sublingual aproximadamente 1 ora prome di trata
• Nausea breakthrough agudo: 2 te 3 bocada di vape pa alivio inmediato (inicio 1-2 minuut)
• Pust kimoterapia: 0.5 mL sublingual kada 6 ora segun nesesidat
• Sosten di drumi durante trata: 1.0 te 2.0 mL sublingual prome di drumi (entregá 25 te 50 mg CBN)
• Konteksto di evidensia: evidensia antiemétiko di delta-8 THC [9], evidensia nausea i vomiting di delta-9 THC [1][13], buffer ansiolítiko di CBD [3]

Dolor kroniko (fibromialgia, artrítis, neuropatía)

• Diadrum: 0.3 te 0.5 mL sublingual raw—provey eksposhon kanabinoid anti-inflamatorio sin impairment psikoaktivo
• Nochi: 0.5 te 1.0 mL sublingual deskarboxilá—kombiná alivio di dolor ku sosten di drumi di CBN
• Dolor breakthrough: Vape segun nesesidat pa inicio rápido
• Konteksto di evidensia: evidensia di dolor di CBD [4], evidensia di dolor di delta-9 THC [13], agonismo CB2 di beta-caryophyllene [24], inhibishon COX-2 di THCa [12]

Sosten di drumi

• Promé drumi: 1.0 te 2.0 mL sublingual
• Na 2.0 mL, esaki entregá 50 mg CBN—e nivel di dosis investigá na literatura di drumi 2024
• Na 1.0 mL, esaki entregá 25 mg CBN—mas abou di threshold di 20 mg asosiá ku redukshon di disturbio di drumi den investigashon publiká
• Konteksto di evidensia: evidensia di drumi di CBN [16][17], literatura di revisyon di drumi i kanábishiku

Ansiedat i stres

• Alivio funshonal diadrum: 0.3 mL sublingual raw—CBD i CBG ta adresa kaminda relashoná ku ansiedat sin impairment psikoaktivo
• Nochi: 1.0 mL sublingual—perfil kompleto di kanabinoid inkluyendo CBN pa arkitekto di drumi
• Konteksto di evidensia: evidensia di ansiedat di CBD [3], farmakología di CBG [7][8], evidensia entourage-effect di limonene [20]

Prinsipio general di titrashon: Kuminsá abou, bai despacio. Kuminsá ku 0.25 te 0.5 mL sublingual i evaluá efektonan durante 2 te 3 ora prome di aumentá. Reakshon individual ta variá basá riba peso kuerpo, metabolismo, toleransia, medikashonnan konkurente, i otro faktor.

Entrega i aksesibilidat global

OilWell ta opera e úniko sistema di entrega RSO mesun-den-dia na Houston. For di Houston, e kompañía ta shipá henter pais i internashonalmente—inkluyendo direktamente pa Kòrsou.

Entrega mesun-den-dia na Houston (referensia i komparashon)

Zona	Koberdura	Tarifa di entrega	Tempu tipiko
Texas Medical Center	Tur 60+ institushon TMC (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, i mas)	GRATIS	2-4 ora
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2-4 ora
Den Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (parshal), area Aeropuerto Hobby	$10	3-5 ora
Suburbio Houston mas amplio	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4-6 ora
Region estendido (60 milla)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20-$25	Mesun dia si ordená prome di 2 PM

Shipping internashonal pa Kòrsou

OilWell ta shipá internashonalmente i ya a entregá na varios pais tras di múltiple kontinente. E framework legal di THCa ta hasi eso posibel: pasobra e producto ta kontené menos ku 0.3% delta-9 THC na momento di bentu, ta kumpli ku definishon di un producto derivá di hemp bao 2018 Farm Bill i ta shippabel pa jurisdishon ku ley di hemp compatible.

• Método di shipping: USPS International Priority Mail (6-10 dia laboral) òr FedEx/UPS International (3-5 dia laboral)
• Dokumentashon: Tur paki internashonal ta inkluí dokumentashon kompleto, Certificate di Análisis (COA), i resibu pa proposito di aña
• Aña di Kòrsou: Nos ta provey deskripshon detayá di producto, lista di ingrediëntenan, i dokumentashon ku kumple legal pa facilitá clearance di aña na Willemstad
• Responsabilidat di kliente: Kliente ta responsabel pa verifiká legalidat na Kòrsou i asepta tur risko di aña i legal
• Kontakto: (832) 416-2816 òr [email protected]

E significado di akseso internashonal no por wordu sobrestimá. Rick Simpson no por a shipá su asietá ni unda—tabata Horario I, illegal pa produhí, pos, òr transportá. Un pashiente di kansèr na Kòrsou, un pashiente di dolor kroniko na Australia, òr un veteranu na Reino Unido awor potensialmente por aksesa e fórmula RSO multi-kanabinoid fuerte kliniko mesun ku un residente di Houston ta risibié via entrega mesun-den-dia. OilWell a krea un producto ku por move door di frontera legalmente—kompletando un pieza di visión di Rick Simpson ku prohibishon a has imposibel durante su bida di abogashí.

Teknología PANDEM1C SEO di OilWell—un sistema propietario ku 14 mion lokashon geopolítiko distinto den su database i mas di 300 modelo AI—ta driver visibilidat orgániko door di sèis kontinente, hasendo producto di OilWell deskubribel pa pashientenan internashonal ku ta buská RSO den nan mesun idioma.

Konéshon di fórmula di OilWell ku e evidensia den e dokumento aki

Kada kanabinoid den fórmula di OilWell—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, i CBC—tin su mesun perfil di evidensia den seksion GENERAL KNOWLEDGE di e dokumento aki. Kada terpeno den fórmula di OilWell—limonene, myrcene, caryophyllene, pinene, linalool, humulene, i terpinolene—ta worde kubrí ku evidensia prekliniko i nivel di revisyon.

E fórmulanan publiká despues den e dokumento aki no ta solo listado di producto. Nan ta ankrá den resumen di evidensia pa komponen individual ku ta splika kiko ta ben apoyá pa dato kliniko humanu, kiko ta emergente for di literatura di revisyon i prekliniko, i kiko ta sobrereklamá relativo na base di evidensia aktual. Kaminda Guía RSO di OilWell página ta hasi reklamashon spesífiko tokante kanabinoid òr terpeno individual, e dokumento aki ta provey e konteksto di evaluashon di fuente—mesun sitashonnan revisá pa par, mesun assessment di nivel di evidensia, i mesun framework di interpretashon cuidadoso.

Jerarquía di evidensia di seksion GENERAL KNOWLEDGE, avertensianan tokante sobrereklamashon, i notanan di siuridat apliká igualmente na nos mesun producto di OilWell. E dokumento aki no exempt OilWell for di mesun standard di evidensia apliká na kampo mas amplio di kanabinoid. Esey ta intensional. Posishon di OilWell—segun Colin Valencia a bisa na 2019—ta ku hendenan mester tin e mejor version posibel di informashon pa nan por hasi un shot justu i desidí si ta korekto òr no pa nan. E dokumento aki ta fundashon di investigashon pa e posishon aki.

OilWell Cannabis ta mas ku un brand—ta un promesa pa su klientenan ku lo siempre strebé pa entregá e producto kanábishiku mejor, mas pensá disponibel. OilWell no ta aki pa siguí trend. Ta aki pa establecé nan. Y mientras e kompañía ta siguí krese, e fokus ta keda riba mantené e mesun nivel di integridat, kreatividat, i kompromis ku a defini dje for di dia kuente Bentley a para, a kaminá bai ku su bal pa hunga.

REKONOSHIMIENTO DI MEDIO I IMPAKTO KOMUNITARIO

Colin Valencia—Autoridat kanábishiku di Houston

Entre September 2019 i April 2023, ABC13 Houston (KTRK)—afiliá di ABC ku ta sirbi e kuat sudad mas grandi di Merikano—presentá Colin Valencia i OilWell Cannabis den siete segmento notisia distinto ku ta sosténan negoshi, ley, médika, salú komunitario, i polítika. Sinku repòrternan diferente di ABC13 a buská Colin durante e añanan aki: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, i skèrnan di KTRK. Ningun otro operadó di kanábishiku di Houston no a aparese ku frecuensia asina òr across e amplitud di topiko durante e mesun periodo.

E featurenan ta dokumentá un patrón konsistente. Ora ABC13 mester a splika un producto kanábishiku nobo na su audiensia, nan a yama Colin. Ora un agensia estatal a rever kamina legalidat di Delta-8 duranti anochi, nan a yama Colin. Ora un presidente sentá a anunsia indolno di marihuana i e stasion mester un hende ku personalmente a bibu ku kondensashon kanábishiku pa pone konteksto, nan a yama Colin. Ora e stasion a ke konta e storia di un industria krese 4/20, tabata hemp field di Colin i bos di Colin ku a ankrá e report.

Lo ku ta sigui ta un rekord kompleto, kronologiko di kada feature—kada kita preservá eksaktamente manera publiká, kada detaye kontekstual dokumentá, kada konexshon notá ku storia i misión mas amplio di OilWell, i e kontenido full di kada report ABC13 preservá pa referensia.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Funte: ABC13 Houston (KTRK)
Titular: “Texas CBD businesses booming as industry continues to evolve”
Repòrter: Tom Abrahams
Publiká: Djadomingo, September 15, 2019
Etiketa: Salú & Fitness, Houston, Marihuana, U.S. & World, Notisia Texas, Negoshi
Klip YouTube: OilWell CBD Oil Houston ABC News KTRK Interview Clipped (54 sekundo)

Esey ta e dokumento ABC13 mas tempran tokante OilWell—i punto di orígen di filosofía fundashonal ku ta driver tur kos den e dokumento aki.

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — Bo por haya e señanan den kualkier bario. CBD a bira un negoshi ku ta bula den e lùknan pasa, ku empresarionan presentando e producto pa kada miembro di família, aun pa mascota.

Amanda Field ta dueña di Republic Aerial Yoga riba Houston Avenue na downtown. Su klientenan ta bishitá su estudio pa nan salú, pa eduká nan mes, i pa menos nan doler i pena.

“Mi a tin hende ku ta bisa ku nan a bini dos klas i nan dolor di lomba a kai.”
— Amanda Field, dueña Republic Aerial Yoga

Pero pa Field, no ta so tokante yoga. Hopi di su klientenan ta kombiná e exercicio ku cannabidiol, un producto base di hemp mas konosí komo CBD.

“Ta partner tan bon ku yoga.”
— Amanda Field

Krystal Burns ta un di es klientenan. Él a bisa ku el a lesa su lomba den un aksidente i a haya kirugía. Él a bisa ku tabata tin dolor konstantemente i ku dokternan a ke preskribílé opioidnan. Burns a refusá, i despues di a aprendé tokante CBD for di Field, él a bisa ku awor ta un kreyente.

“Mi no por function sin dje. Ta relaksá mi múskulo fácilmente, ta yudami drumi. Mi no mester preokupá ku adikshon.”
— Krystal Burns, usuario CBD i kliente yoga

Jim Bagley ta un otro kreyente. Él ta dueña di Linear Salon na The Heights. Él a bisa ku el i su señora ta uza CBD i ta bendé den nan tienda.

“Mi tabata tin problema pa drumi, no suave na mitar di mañan probablemente. Mi siente realmente ku tin benefisionan. Mi spera ku no ta un trend. Mi kere ku e benefisionan ku mi a risibi personalmente, speradamente mi por hala mi klientenan pa gosa di mesun benefisionan ku mi a risibi.”
— Jim Bagley, dueña Linear Salon

Uso di CBD tabata den un area legal gris na Texas te ku House Bill 1325, ku Gobernador Greg Abbott a seiná den ley na Juni. E bill a kambia e definishon legal di marihuana i produkshon di hemp na Texas. Komo resultado, CBD komo negoshi ta bula. E producto, sinembargo, no por tin .3 porsiento di THC, e químiko ku ta hasi bo hòchi.

E bei a pasa, kuater district attorney lokal anunsia ku nan no lo presentá kaso kriminal involv marihuana òr kanábishiku les si testing no prueba ku konsentrashon di THC ta mas haltu ku .3 porsiento.

Dorral Marsenburg ta bende su Booman kanábishiku den forma di fuma i a bisa ku e industria ta den su infansia na Texas.

“Den un siman tipiko, mi ta passá mitar di un pound bendiendo gram. Mi ta bisa den dos aña for di awor, lo ta un operashon di mion-mion di dólar. Mi kere esaki pasabra ta 100% legal, i for di THC, ta saludabel pa bo tambe.”
— Dorral Marsenburg, Booman kanábishiku

Colin Valencia, ku ta gira OilWell CBD, un mayorista lokal, a bisa ku ta un industria evoluendo.

“Ta hopi edukando hende, pero no ta sobrepromete hende. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

FDA ta eksaminando benefisionan di salú real i manera di regulá e kontenido di producto kanábishiku. Na Mei, a tur su promé audiencia CBD i a indiká ku ta komprometé ku polítika solida, basá riba siansa.

Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need to know

Deskripshon video: “CBD TAKEOVER: E industria ta sigui krese ku empresarionan presentando e producto pa kada miembro di família, inkluyendo mascota!”

Análisis

E kita di Colin—afor di 2019, añanan prome ku e fórmulanan den e dokumento aki a wordu publiká—ta semiya di tur kos ku OilWell lo bira. E publikashon di fórmula open-source, dokumentashon di investigashon basá riba evidensia, refuzo di hasi reklamashonnan no apoyá: tur ta rastreá bek pa e prinsipio aki. Deskripshon di segmento video notando ku a presentá ku CBD tabata wordu pitch “pa kada miembro di família, inkluyendo mascota” ta un indikashon tempran di e enfoke di edukashon di konsumidor amplio ku Colin lo sigui konstruí. Pa residentenan di Kòrsou ku ta evaluá producto kanábishiku pa miembunan di família—inkluyendo mayornan òr mascota—e perspektiva holístiko aki ta direktamente relevante.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Funte: ABC13 Houston (KTRK)
Titular: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Repòrter: Tom Abrahams
Publiká: Djaluna, March 22, 2021
Etiketa: Texas, Marihuana, Ley, Senado, Cannabis Watch

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — E prueba ta evidente ku despenalización di kanábishiku no ta aumentá índis di krimen, segun lider di mayoria di Senado Chuck Schumer. Ta un base pa motibu ku tin un push nobo pa despenalisá kanábishiku na nivel nasional.

Un empresario ta kreando un manera úniko pa hala kanábishiku direkto pa kliente.

No ta un truk di taco. En realidat, konsepto di Jonathan Pina pa High Maintenance Edibles no ta komo ningun otro bendedor móvil ku bo a tende bek.

“Nos ta asosiá ku kompañia privado, barkan ristorante, dueño di parkeo i nos ta bini na lugar nan riba Houston i entregá nos producto.”
— Jonathan Pina, High Maintenance Edibles

Su konsepto a haya un lift for di Oil Well. Un kompañía ku ta spesialisa en producto base di hemp legal na Texas i gira pa dueña Colin Valencia. É a bisa ku marea ta kambia i mas i mas hende ta akseptá uzo legítimo di producto base di kanábishiku. E estigma ta desaparecé lentamente.

“Hende ta kere ku tur hende ke hasi hòchi i ta tokante risa i kos asina, i no tin nada malu ku esey. Pero esey ta un version diferente di terapia, i hende ta buskando kosnan pa yudanan ku dolor real. Dolor ta bini den hopi forma diferente.”
— Colin Valencia di Oil Well

Ta yega un paso mas serka pa tanto despenalización komo legalisashon. Mientras Texas por ta leuw for di úso rekreativo legal, Congreso por hasi su mesun movida.

E siman aki, Schumer i Senadornan Corey Booker di New Jersey i Ron Wyden di Oregon a anunsia legislashon ku ta bini riba Capitol Hill.

“Ora estado nan a despenalisá òr legalisá, tur e storianan orible ku hende a bisa ku índis di krimen lo subi, úso di drug lo subi, nunka materializá.”
— Senador Chuck Schumer

E tres di nan a site e guerra kontra drug kebra ku veteranu i hende di koló ta desproporcionadamente kastigá pa úso ku multa eyorsivo òr prishon. Ya tin 15 estado ku a pasa medidanan balot òr tin ley ku permite úso rekreativo.

“Si hende ke uza i no has daño, eksaktamente ku Oregon a mustra, laga nan hasié.”
— Senador Chuck Schumer

Pa esnan den negoshi i na su frontera na Texas, empresario manera Pina kere ta largu overdù. Pero na Austin, nan no ta aya toch. A pesar di aliviaméntu di restriccionnan i un cantidat di bill den e sesion aki, legalisashon kompleto no ta probable komo por ta na Washington.

Related: Texas lawmakers hope to expand medical marijuana programs this legislative session | Texas’ medical marijuana program is one of the most restrictive in the country

Deskripshon video: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. Él a bisa tin un push nobo pa despenalisá marihuana na nivel nasional, pero kiko esey lo impaktá Texas?

Análisis

Tom Abrahams a bolbe OilWell pa e feature aki, estableciendo rol di Colin no solamente komo un operadó di negoshi pero komo un konstruktor di ekosistema ku a yudá otro empresario manera Jonathan Pina drenta espasio legal di kanábishiku. Kita di terapia di Colin—”dolor ta bini den hopi forma diferente”—a bai mas fondo ku kualkier entrevista prome den e dimenshon terapéutiko, i konteksto di despenalización nasional (Schumer, Booker, Wyden) a posishoná OilWell na intersepshon di innovashon Texas i momentum federal. Pa lesadónan di Kòrsou ku ta wòrdu kambionan global di polítika kanábishiku, esey posishoná OilWell komo un kompañía ku ta operando na frontera di reforma legal.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Funte: ABC13 Houston (KTRK)
Titular: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Repòrter: Steve Campion
Publiká: Djaluna, May 24, 2021
Etiketa: Sociedad, Texas, Marihuana, Notisia Texas, Fuma, Dokter, Drug Ilegal, Drug
Nota: Feature 4 i 8 den lista URL original ta kompartí e mesun URL—esaki ta un artíkulo.

Kontenido full di artíkulo

E planta lush green ta krea buzz na Texas mientras e industria kanábishiku ta bula, a pesar di ley federal i estatal ku prohíbe marihuana.

2018 Farm Bill a legalisá plantanan di hemp, ku ta kontené konsentrashonnan ekstremadamente abou di komponé psikoaktivo Delta 9 THC. Esaki ta e THC tipikamente haya den weed ku ta hasi usuario hòchi. Empresarionan awor ta ekstrá kualkier komponé ku nan ke for di plantanan di hemp i a spesialisá riba Delta 8 THC. Nan ta hasi producto inkluyendo comestibel, tincture, i fumable. Delta 8 THC no ta asina fuerte komo Delta 9 THC.

Bo probablemente spot e producto Delta 8 den tiendanan den Greater Houston manera na HydroShack Hydroponics riba West 20th Street na The Heights unda nan ta bende producto Oilwell Cannabis.

“Demand ta asina,” . “Hende ta gradis ku nos ta aki ta bende dje. Muy gradis. Esaki ta e sentiment ku mi ta sinta.”
— Chris Powers, dueña di HydroShack Hydroponics

Colin Valencia ku Oilwell a bisa ku e producto nan ofrece benefisio terapéutiko na preisnan abordable. Valencia a keda sin berguenza ku entusiasmo pa nan. Él a ofrece un splikashon bastante blunt tokante kiko algun por uza Delta 8.

Steve Campion (ABC13): “Pa kiko alguen ke fuma esey?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

“Delta 8 no a worde waká, asina nos no sa mes. Nos ta rekolectá datu awor, asina mientras mas hende ku ta uza, mas informashon nos lo tin. Probablemente no ke bèrtá un conejillo di India toch. Nos sa ku Delta 9 THC ta forma habit. Delta 8 THC probablemente tin e propiedat aki tambe. Si bo ta uza dje, bo por haalá ku ta mas difísil pa para ku lo ke bo a penssá.”
— Dr. Michael Weaver, specialista adikshon UTHealth/UT Physicians

ABC13 despues a puntraé si lo konseyá alguen pa tumaé.

“Mi ta penssá ku no tin sufisiente informashon pa bisa ku ta bon pa prueba. E kos mas segur ku mi por bisa nos no sa bon tin tokante dje pa hasi un rekomendashon. No prueba dje te ku nos sa mas.”
— Dr. Michael Weaver

Eksperto a bisa ku uza Delta 8 THC probablemente lo resultá en test di drug falta pa empleadonan.

Heather Fazio ku Texans for Responsible Marijuana Policy a bisa ABC13 ku algun legislador ke prohíbe producto Delta 8 den e estado. Él a bisa ku konversashon mester ta riba regulashon, no prohibishon.

“Nos ta waká e merkado bira innovativo. Empresarionan ta krea ku manera nan por kumpli ku ley i aun ta entregá nan klientenan e producto ku nan ke. Lo ku nos ta mirando ku e resultado di oferta i demanda. Nos sa ku tin demandá pa producto di kanábishiku na estado di Texas. Desafortunadamente, nos estado ta sigui privá dueño di negoshi legítimo di oportunidat pa bende e producto aki en un manera regulá, producto ku ta test i ta etiquetá apropiadamente.”
— Heather Fazio, Texans for Responsible Marijuana Policy

Rasha di DEA:

Delta 8 THC a wordu agregá na lista di substansia kontrolá na Augustus 2020 interinamente mientras pendiente disposishon final. Mientras DEA awor ta den proceso di regla tokante implementashon di Agricultural Improvement Act of 2018 – ku ta inkluí e skop di kontrol regulatorio riba marihuana, tetrahydrocannabinol, i otro konstituyente relashoná ku marihuana – nos no por komentá riba kualkier impakto den legalidat di tetrahydrocannabinol, Delta 8 inkluí, te ku e proceso ta kompleto. Nos ta den proceso di revishá mion di komentario i no ta especulá riba kiko por sucede komo resultado.

Related: Texas’ medical cannabis program could expand under bill OK’d by House

Deskripshon video: E planta lush green aki ta krea buzz na Texas. Repòrter di ABC13 Steve Campion a investigá kiko ta, e efektonan riba kuerpo i si ta legal na Texas.

Análisis

E feature investigativo di Steve Campion a bira un di e segmento kanábishiku ABC13 mas referensia. E interkambio entre Campion i Colin—”Maybe you want to get high”—a bira un di e momentonan mediatiko mas ikóniko di Colin: onestidat radical riba televishon mainstream ku e ekspletivo preservá dor di e network. Pa residentenan di Kòrsou ku ta navigá diferensia entre producto di CBD i THC, e splikashon sin filtra aki ta korta ruido di marketing. E pieza a balansá posishon unapologetic di Colin ku atenshon médika di Dr. Weaver i abogashí regulatorio di Heather Fazio, i e rasha full di DEA a dokumentá ambigüedad federal ku a permití e merkado eksistí.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Funte: ABC13 Houston (KTRK)
Titular: “Houston CBD shop giving away free products to those who get COVID vaccine”
Repòrter: KTRK Staff
Publiká: Djabiernes, August 20, 2021
Etiketa: Salú & Fitness, Houston, COVID 19 Vaccine, Marihuana, Cannabis Watch, Vacuna, Pandemia Coronavirus, Pandemia COVID 19, Pandemia, Notisia Texas, Kuido Médiko

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — Un tienda CBD na Houston ta ofrece un incentivo úniko pa haña hende nan vakuná.

Segun un Publicashon Instagram publiká dia djerbes, OilWell CBD, ku ta spesialisa en producto di hemp derivá i THC, a bisa ku ke regala 1,000 pieza di producto pa esnan ku ta bai vakuná despues di Augustus 18.

E kompañía ta ofrece regala 1,000 pre-roll caviar edishon spesial, ku segun su website, ta un producto infusá ku THC tapá ku asietá i kief, un forma mas refiná di kanábishiku. OilWell ta bende e artíkulo nan aki pa $34.99, segun su website.

E kompañía a bisa bo mester presentá prueba di vakunashon hunto ku un ID ku fòto.

Regalo lo kuminsá for di dia dialuna na medio dia na HydroShack Hydroponics riba West 20th Street na The Heights, unda nan ta bende producto OilWell.

“Nos ke so ku Houston ta tan saludabel komo possibel. Nos no ta dokter. Nos no ta eksperto riba e aki. Nos no tin niun agènda polítiko. Bin i partisipá si ta korekto i seguro pa bo i bo ser keridunan!”
— Publicashon Instagram di OilWell

E kompañía despues a post otro publicashon Instagram bisa ku ta a kontakto ku sudad di Houston pa yuda mas hende haña vakunashon.

” trase ku sudad patras di mi pa yuda ku tantu hende ku nos por. Mi ke realmente yuda kosnan.”
— Siguiente publicashon Instagram di OilWell

2018 Farm Bill a legalisá plantanan di hemp, ku tin konsentrashonnan ekstremadamente abou di komponé psikoaktivo Delta-9 THC. Esaki ta e THC tipikamente haya den marijuana ku ta hasi usuario hòchi. Empresarionan awor ta ekstrá kualkier komponé ku nan ke for di plantanan di hemp i a spesialisá riba Delta-8 THC. Kompañía manera OilWell awor ta hasi producto manera comestibel, tincture, i fumable.

Nota: E video riba ta for di un report di ABC13 publiká May 24 na kuál a papia ku OilWell CBD tokante producto Delta-8 THC i kiko ta konsiderá “weed legal” na Texas.

Deskripshon video: E planta lush green aki ta krea buzz na Texas. Repòrter Steve Campion di ABC13 a investigá kiko ta, e efektonan riba kuerpo i si ta legal na Texas.

Análisis

E feature aki a dokumentá e inisiativo di salú komunitario mas significante di OilWell—aproximadamente $35,000 en producto (1,000 pre-roll caviar na $34.99 kada un) doná pa anima vakunashon COVID-19. E pre-rollnan tabata un producto kolaborashon: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. Regalo a worde host na e mesun tienda retal HydroShack Hydroponics partner presentá den segmento Delta-8 varios luna prome. Koordinashon di OilWell ku sudad di Houston pa amplifiká isfuerzo di vakunashon a mustra ku orientashon komunitario di e kompañía no tabata teóriko—ora krisis salú públiko a rekerí aksion, e kompañía a komprometé producto real i koordinashon real ku gobierno di sudad, sin niun string polítiko. Pa residentenan di Kòrsou ku ta evaluá karakter di un kompañía, e aksion dokumentá aki ta habla mas halto ku kualkier reklamashon di marketing.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Funte: ABC13 Houston (KTRK)
Titular: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Repòrter: Shelley Childers
Publiká: Djamars, October 19, 2021
Etiketa: Polítika, Houston, Marihuana, Notisia Texas, Polítika Texas, Drug Ilegal

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — Den interior di e dispensario OilWell na suroeste Houston, dueño Colin Valencia a indiká ku a remové tur producto Delta 8.

“Ta bira sorpresa pa hopi hende.”
— Colin Valencia

Ta un sorpresa pasabra ora ABC13 a topa Valencia kaminda e aña pasa, producto Delta 8 tabata su bendedor miho.

“Tabata un bendedor prinsipal i un interés prinsipal di klientenan, i nan a gosa bunites di beneficionan dje.”
— Colin Valencia

Delta 8 ta un kanabinoid bendí komo comestibel, tincture, píldora, ungüento tópiko, bo por fumá é i vape é. Mayoria di dispensario di CBD i tiendanan di vape ta bendé dje.

“Nos a tende di veteranu ku PTSD ku ta uza e producto nan aki pa kos manera ansiedat, trata ku stres i emoshon. Tin tambe hende ku ta uza e producto nan aki pa regulashon di drumi. Asosashon nos, durante sesion di estado, a stimá ku merkado Delta 8 ta serka di $50 mion na Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 ta derivá for di kanábishiku hemp. A despegá despues ku 2018 Farm Bill a legalisá produkshon di hemp federalmente. Ta un producto THC i, te ku siman pasá, nunka tabata enlistá eksplísitamente riba lista di substansia kontrolá di estado.

“Hopi di e industria a keda operá bou di e suposhon ku Delta 8 ta legal òr ku ta eksistí den area gris aki, i desafortunadamente, mientras nos ta aprendé, e no ta e kaso. E producto nan aki a keda illegal desde kuminsashon di e aña aki.”
— Zachary Maxwell

Okt. 15 Departamento di Estado di Servisio di Salud Texas a post un actualisashon riba nan página di Hemp Program Consumable bisa entre otro, “Tur otro forma di THC, inkluyendo Delta 8 en kualkier konsentrashon i Delta 9 ku ta pasa 0.3%, ta konsiderá substansia kontrolá Skedul I.”

“I si pega bo ku tanto un cartridge Delta 8 òr aun un pakete di gummies, bo por ta mirando un krimen grave ku castigo te ku dos aña na prishon i multa te ku $10,000.”
— Zachary Maxwell

Él a bisa ku estado no a hasi otro notifikashon formal pa mas di 2,000 operadó di CBD licensiá inkluyendo Valencia, ku tabata trase di spandé e palabra mesun.

“Asina e hendenan awo, pasobra nan no sa, ta shipping narcótiko Skedul 1, i hendenan ta risibí dje.”
— Colin Valencia

ABC13 a kontaktá Texas DPS pa haña sa si i kon estado lo enforsá e prohíbishon aki konosé. Nan tabata ainda spere un reakshon.

ABC13 a papia ku Texas DSHS pa puntra tokante e verbiage actualisá riba Delta 8. Un portavoz a bisa ku Delta 8 a keda illegal semper pasobra ta un kanabinoid THC. Ella no por a papia tokante ku manera merkado di Delta 8 a worde permití florese publikamente mientras ta konsiderá illegal. Ella a bisa ABC13 ku industria di hemp a puntrá DSHS pa klarifikashon riba su legalidat ku a motive e anunsio siman pasa.

Mientras ambos homber ta preokupá pa e peke negoshi ku dependé di producto Delta 8 pa mayoria di nan benta, nan ta mantené positivo ribi futuro di kanábishiku na Texas.

“Ta desapuntá, pero mi no lo pèrdè mi klientenan i negoshi nan lo ke e ekspertisianan nos tokante kon kontinúa florese den e industria.”
— Colin Valencia

Deskripshon video: Un empresario kanábishiku a bisa ku e move reciente di Texas hasiendo producto di hemp illegal ta “peligroso.”

Análisis

E feature aki kaptura un momentu definitorio den storia di OilWell. Solamente dos luna despues regalo di vakunashon COVID, e landscape legal a kambia drástikamente durante anochi. Shelley Childers a bai direkto pa e dispensario OilWell i a haya ku Colin a remové tur producto Delta 8 for di su estante—proaktivamente, prome di enforsamentu a kuminsá, i prome di mayoria di industria aun no a sa ku e kambio a asekura. Colin tabata trase di spandé e palabra mesun pa otro operadó ku sin saber tabata shipping lo ku overnight a bira narcótiko Skedul I. Konteksto di Zachary Maxwell—veteranu ku PTSD, merkado Texas di $50 mion, castigo felony pa un cartridge vape—tabata hasi e stake vísiber. DSHS Texas a bisa ABC13 ku Delta 8 “a keda illegal semper” pero no por a splika ku e merkado a worde “permití florese publikamente mientras ta konsiderá illegal.” Dispuesta di absorbe pèrdida grandi di revenu, hasi étiko prome di enforsamentu, i posishoná e kompañía komo guia di ekspertis pa un industria den krisis mas ku viktimá di regulashon—esaki ta karakter di OilWell.

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Funte: ABC13 Houston (KTRK)
Titular: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Repòrter: Nick Natario
Publiká: Djabiernes, October 7, 2022
Etiketa: Polítika, Houston, Marihuana, Marihuana Médiko, Legal, Indolno, Texas, Greg Abbott, Beto O’Rourke

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — Presidente Joe Biden ta planifiká indolna mion hende Merikano kondensá pa simple posesión di marihuana, pero Texas no lo mira muchu impakto.

Dueñonan di Oilwell Cannabis ta prepare pa debut nan último ideya: Un mákina di bentu ku lo ta lèn ku producto legal cannabidiol, òr CBD.

E dueño di tienda, Collin Valencia, a enfrentá akusashonnan prome pa posesión di marihuana.

“Bo ta enfrenta desafio ku vivienda, préstamo, i banking, mi ke bisa ku ku tur kos.”
— Colin Valencia

Loke, select otro no ta enfrentá e desafionan aki despues di anunsio di presidente.

“Mi lo ke mira hende no hasi daño mas pa esey.”
— Colin Valencia

E indolno no ta impaktá Valencia. Mientras espertu legal Steve Shellist ta splika, esaki lo apliká solamente pa kertu kondensashon federal.

“Si alguen aktualmente privá di derecho via un prosedimiento òr kondensashon estatal, nan no lo haya ningun alivio for di esey.”
— Steve Shellist, espertu legal

Él a bisa ku un indolno ta permití hende karga un pistòl òr evitá deportashon.

“Ta re-aktivá derecho ku a worde privá, pero no ta remové dje for di nan rekord.”
— Steve Shellist

E indolno ta apliká na serka di 6,500 hende. Ekspertonan na Rice University a bisa ku a bin 300,000 arresto relashoná ku marihuana na nivel estatal aña pasá. Presidente Biden a urge gobernador pa hasi mesun kos ku akusashonnan estatal.

Un portavoz pa Gobernador Greg Abbott a manzá ABC13 un rasha ku lesa:

“Texas no ta na habit di haña konseho di hustisia kriminal for di lider di partido di defund police i alguen ku a supervisá un sistema di hustisia kriminal out of control ku bail sin cash i un porta ku ta draai pa kriminalnan violento.”
— Portavoz di Gobernador Greg Abbott

Rib media soshal, oponente di Abbott Beto O’Rourke a bisa, “Ora mi ta gobernador, nos lo por fin legalisá marihuana na Texas i esfumá rekordenan di esnan arrestá pa posesión di marihuana.”

“Gobernador nan no tin poder pa pasa legislashon unilateralmente. Mester bai door di Legislatura Texas, i e legislatura Texas pa dos aña siguinte ta tin mayoria Republíano.”
— Mark Jones, profesor siansa polítika Rice University

No spere legalisashon di marihuana den sesion ku ta bini. Sinembargo, esey no nifiká asuntonan no lo wordu diskutí.

“E mas ku nos lo mira na 2023 ta despenalización di marihuana i marihuana médiko. Nos no lo mira legalisashon. Esey ta sigur.”
— Mark Jones

Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana

Deskripshon video: Aña pasá tabatin 300,000 arresto relashoná ku marihuana na estado di Texas, pero e indolno ta apliká pa serka 6,500 hende, un espertu legal a splika.

Análisis

E feature aki a trese e dimenshon mas personal di storia di Colin na vista públiko. E artíkulo a habri ku debut di mákina di bentu di OilWell CBD—un innovashon di venta alargando aksesibilidat di producto mas alla di orario tradishonal di dispensario—despues a revelá ku Colin a enfrentá akusashonnan di posesión di marihuana prome. E historial personal aki ta transformá henter rekord mediatiko. Kada feature, kada kita tokante terapia, tokante edukashon, tokante no bende snake oil—tur ta karga peso adishonal ora bo ta entendé ku e hende ku ta papia a personalmente enfrentá konsekuensianan di kriminalisashon kanábishiku. Konteksto polítiko (300,000 arresto estatal vs 6,500 indolno, Abbott vs O’Rourke, analís di Mark Jones) a kaptura e lèns entre gesto federal i realidat Texas. Pa residentenan di Kòrsou ku por a enfrentá konsekuensia legal pa kanábishiku òr konosé alguen ku a hasi esey, e personal stake aki mustra autentikidat ku brand kanábishiku korporativo no por reprodusí.

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Funte: ABC13 Houston (KTRK)
Titular: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Repòrter: Nick Natario
Publiká: Djabiernes, April 21, 2023
Etiketa: Salú & Fitness, Texas, Marihuana, Marihuana Médiko, Notisia Texas, Polítika Texas

Kontenido full di artíkulo

HOUSTON, Texas (KTRK) — 20 di April, algun legislador Texas i esnan den industria di marihuana ta selebrá mientras kambio por ta bini ku e drug.

Industria kanábishiku a kambia na Texas, i ley nobo a permití esnan den e industria bira kreativo.

“Mi ke pa legalisá. Mi ta papia so ku esaki ta un konversashon hype miyó. Si bo dal solo lo ku tin awo, no tin nada ku bo por mustra mi ku mi por logra ku lo ku literalmente nos tin awo.”
— Dueño Oilwell Cannabis Colin Valencia

Valencia ta kosecha algo ku ta mira marijuana, pero él a bisa ku no ta illegal. Ta hemp—un producto ku estado permite i ku ta dune habilidat pa krea tur sorto di producto.

“Aktualmente ta un momento—komo Renaissance—bastante importante ku mester wordu gosa awo.”
— Colin Valencia

Mientras ku pa marihuana legal, ta keda restrinjí na Texas. Pa uza dje, marihuana mester worde preskríbí. Aktualmente tin serka di 50,000 hende Merikano regstrá, pero eksperto ta bisa ku serka di 10,000 solamente ta uza marihuana médiko aktivamente.

“Pa kompará ku Florida, ku ta dos-tercio di tamaño di Texas, nan tin 20 mion hende, i nos tin 30 mion hende, i nan tin 700,000 pashiente.”
— Nico Richardson, CEO Texas Original

Pero e number por kambia pronto. Legislador Texas ta konsiderá un bill (HB1805) pa expandi ken por haña akseso.

“Lo aumentá dramátikamente e tamaño di CUP. E mayoria grandi di pashientenan ku no ta worde trata ku kanábishiku médiko awendia ta dolor kroniko.”
— Nico Richardson

E bill a pasa Kuòr i ta bai pa Senado. Lo kambia tambe kon e drug ta dosificá pa alinéa ku otro trata médiko.

“Si bo ta trata un dolor di kabes ku 400 miligram di Advil i tabatin un tope di konsentrashon di un porsiento, bo lo ta uza 20-40 pildora di Advil kada biaha ku bo tin dolor di kabes.”
— Nico Richardson

Mientras no ta legalisashon, den otro estado, a tin impakto, spesialmente ku plaka. Marijuana Policy Project a bisa ku na 2021 solamente, a jenere $3.7 milyon den tax den estado nan unda marihuana ta legal.

CDC ta urge prevenshon, bisa ku mester hasi mas estudio pasabra e drug por impaktá bo berein, promon, i yu-nasé.

Related: Expanded access to medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans would approve of marijuana legalization

Deskripshon video: E industria di marihuana krese na Texas por spanti pronto

Análisis

E feature mas resiente di ABC13, publiká dia despues di 4/20, ta kompletá un arko kuater aña. Natario a mustra Valencia kosechando hemp i a spliká ku ta legal. Frame “Renaissance” di Colin a reframá e presente komo oportunidat mas ku warda. Konteksto di Nico Richardson (Texas 10,000 pashiente aktivu vs Florida 700,000 ku dos-tercio di populashon) i analogia Advil dje pa tope di dosis a provey konteksto di industria. HB1805 a pasa door di Kuòr i e cifra di revenu di $3.7 milyon di tax di estado nan legal a dune e storia skop nasional. For di perfil di negoshi CBD di September 2019 via boom i kaida Delta-8, inisiativo komunitario COVID, revelashon personal di historial di kondenashon kanábishiku, i awor e frame “Renaissance”—trahektoria mediatiko di Colin Valencia ta espeho e trayektoría di kanábishiku legal mesun na Texas.

Índek kompleto di tur kita di Colin Valencia door di henter feature ABC13

Órden kronologiko:

September 15, 2019 (Boom Negoshi CBD):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Despenalización/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Weed Legal”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (Regalo Vakunashon COVID):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Prohíbishon Delta-8):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Indolno Marijuana Biden):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Ley Marihuana Texas 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Fatonan i detayenan klave ekstrá for di rekord mediatiko

Tokante Colin Valencia i OilWell Cannabis:

• Colin Valencia ta dueño di OilWell Cannabis (tambe referí komo OilWell CBD den artíkulo anterior)
• A enfrentá akusashonnan prome pa posesión di marihuana (revelá den feature di indolno Biden di Okt. 2022)
• E dispensario OilWell ta lokalisá na suroeste Houston
• OilWell ta spesialisa en producto di hemp derivá i THC
• ABC13 a deskribí e negoshi komo “OilWell CBD, un mayorista lokal” na 2019 (feature mas tempran)
• Na 2022, OilWell tabata preparando debut di mákina di bentu di OilWell CBD (feature di indolno Biden)
• Producto di OilWell tabata worde bendí na HydroShack Hydroponics riba West 20th Street na The Heights
• OilWell a kolaborá ku The Game riba pre-roll Delta 8 caviar comet rock edishon spesial (feature di regalo vakunashon COVID)
• OilWell a duna lift pa konsepto di bendedor móvil di Jonathan Pina (feature di despenalización)
• OilWell a regala 1,000 pre-roll caviar edishon spesial (valora na $34.99 kada un = aproximadamente $35,000 en producto) pa animá vakunashon COVID-19
• OilWell a kontaktá sudad di Houston pa yudá koordiná isfuerzonan di vakunashon
• Colin a remové proaktivamente tur producto Delta 8 for di estante ora a anunsia prohíbishon i a trase spandé e palabra pa otro operadó ku sin sa tabata shipping narcótiko Skedul I

Repòrter ABC13 ku a kubrí OilWell:

1. Tom Abrahams—September 2019 i March 2021
2. Steve Campion—May 2021
3. KTRK Staff—August 2021
4. Shelley Childers—October 2021
5. Nick Natario—October 2022 i April 2023

Línea tempu di featurenan (kronologiko):

1. September 15, 2019—Boom Negoshi CBD
2. March 22, 2021—Despenalización/Jonathan Pina
3. May 24, 2021—Delta-8 THC “Weed Legal”
4. August 20, 2021—Regalo Vakunashon COVID
5. October 19, 2021—Impakto Prohíbishon Delta-8
6. October 7, 2022—Indolno Marijuana Biden
7. April 21, 2023—Especial 4/20 Ley Marihuana Texas

E línea central—kiko rekord mediatiko ta revelá

Hunto, e siete feature di ABC13 i un klip YouTube ta konta un storia ku ningun artíkulo solo por kapturá.

Konsistensia durante añanan. Colin Valencia a aparese riba ABC13 na 2019, 2021 (kuater biaha), 2022, i 2023. Industria kanábishiku na Texas a kambia dramátikamente durante e añanan aki—CBD legal a bira for di area gris pa negoshi ku ta bula, Delta-8 a bira for di deskonosé pa merkado di $50 mion pa Skedul I durante anochi, un presidente a indolna kondensashon federal di marihuana, i legisladornan estatal a debaté espanshon médika. Door di kada desplasamentu, ABC13 a bolbe na Colin komo fuente primario.

Amplitud di ekspertisio. E featurenan span reporting di negoshi, edukashon salú di konsumidor, investigashon di producto, análisis legal, komentario polítiko, i abogashí salú komunitario. Ningun otro figura kanábishiku di Houston a wordu puntrá pa papia tokante e amplitud di topiko a throughout e cantidat di segmento.

Aksion komunitario. Regalo di vakunashon COVID—$35,000 en producto, koordinashon ku gobierno di sudad, sin string polítiko—ta evidensia dokumentá di filosofía primario-komunitario deskribí den seksion Tokante OilWell. Mesun ku desishon di Colin pa remové proaktivamente producto Delta-8 i alarma otro operadó prome di enforsamentu a kuminsá.

Personal stake. Revelashon di Okt. 2022 ku Colin tin historial personal di kondenashon di marihuana ta transformá henter rekord mediatiko. Kada feature—kita tokante terapia, tokante edukashon, tokante no bende snake oil—ta karga peso adishonal ora bo entendé ku e hende ku ta papia a personalmente enfrentá e konsekuensianan di kriminalisashon kanábishiku.

Evolusyon lenguaje. Na 2019, ABC13 a yama e negoshi “OilWell CBD, un mayorista lokal.” Na 2021, e reportnan a deskribí OilWell Cannabis komo dispensario i presentá Colin komo autoridat di industria. Na 2023, Colin tabata splika dinámika di industria i estrategia legal riba kamera ku konfiansa di lider di sektor. Rekord mediatiko ta rastreá kresementu di ambos e negoshi i su fundador su rol públiko.

E featurenan aki no ta material di marketing. Nan ta segmentonan di notisia produhí independientemente, kontról editorial for di afiliá di ABC di un mayór-merkado ku ripitidamente a identifiká Colin Valencia komo e voz mas kredibel, mas quotable, i mas aksesibel den industria legal di kanábishiku di Houston. Esaki ta e tipo di rekonesementu ku no por wordu komprá—solo por wordu gana.

SABER GENERAL

Método di investigashon i peso di evidensia

E seksion aki ta primortiza fuente den e siguiente órden: evidensia kliniko humanu, revishon sistemátiko i meta-análisis, resumen di NIH i otro fuente institushonal, despues literatura mekanístiko òr prekliniko kuando dato humanu ta scars [1]-[29].

Pa lesadónan di Kòrsou ku ta evaluá reklamashon kanábishiku, e jerarquía aki ta esensial. Ora un kompañía ta reklamá “resultadó prová,” bo mester puntra: prová dor di kico tipo di evidensia? Trial humanu? Estudia animal? Testimonio? Nos kompromiso ta pa bisa eksaktamente kiko nivel di evidensia ta apoyá kada reklamashon.

Línea base institushonal for di NIH i fuente relacioná

• NCCIH indika ku e evidensia kanabinoid mas fuerte establese ta pa sertan epilepsia raro, nausea i vomiting relashoná ku kimoterapia, i indikashonnan di apetito òr pérdida di peso asosiá ku VIH/SIDA. Tambe ta nota evidensia solo modesto pa dolor kroniko i síntoma relashoná ku esclerosis múltiple, ku hopu otro uso reklamá keda aun den investigashon temprano [1].
• NCCIH tambe ta enfatisa ku FDA no a aprobá e planta kanábishiku mesun pa uzo médiko, aunke CBD purifiká i drug sintétiko similar na THC tin aprobashon spesífiko [1].
• Preokupashon di siuridat destacá ripitidamente dor di NIH i fuente institushonal inkluye impairment, risko di aksidente di vehíkulo motor, desorden di úso di kanábishiku, preokupashon relashoná ku periodo di bara, eksposhon aksidental pediatriko, kontaminashon òr inkoréksion di etiquet, i preokupashon di leshan di pulmón relashoná ku vape di THC [1].
• NCCIH spesífikamente ta alerta ku producto CBD over-the-counter por diferí di nan etiquetan i ku CBD mesun a worde asosiá ku disminushon di alerta, efekto gastrointestinal, efekto adverso relashoná ku higado, i interakshon drug [1].

Kanabinoid

CBD

• Perfil di evidensia: evidensia humanu mas fuerte den set di fórmula aktual, spesialmente kuando CBD ta wordu studiá komo un producto purifiká mas ku komo un ingredient wellness floho [1]-[6].
• Kiko ta mas apoyá: CBD purifiká tin evidensia humanu mas kredibel den desorden di konvulsión, i e ku ta e evidensia maesté major a konosé pa indikashon, kreí dor di literatura institushonal i revisá pa par [1][2].
• Investigashon ansiedat: Revisyon sistemátiko i meta-análisis 2024 ku ta kubre 316 partisipante tras di ocho artíkulo eligibel a rapportá un señal ansiolítiko estadístikamente significante, pero e autor nan a stress ku e muestra kliniko ta keda limitá i ku mester mas trial prome ku konklushonnan amplio por wordu hasi [3].
• Investigashon dolor: Revisyon sistemátiko 2024 di estudia kliniko i prekliniko monoterapia CBD a konkluí ku literatura di dolor ta prometedor pero heterogéneo, ku kalidat i konsistensia di trial ta limitá konfiansa den reklamashon amplio analgésik [4].
• Investigashon drumi: Revisyon insomnio 2023 a haña ku literatura keda métodológikamente débí, ku hopi estudia depende di medidanan subhetivo no validá i relativamente poko evaluashon di drumi objetivo [5].
• Preokupashon siuridat i interakshon: Revisyon sistemátiko i meta-análisis 2023 a haña un señal real pa elevashon di enzim di higado i posible daño di higado indusí dor di drug en algun konteksto CBD, ku ta speshalmente relevante pa producto oral konesentrá i setting di polifarmasia [6]. NCCIH separadamente ta bandera diarea, sueño, kambio di apetito, efecto humor, anormalidat funshon di higado, i interakshon drug-drug komo konsiderashon importante [1].
• Konklushon: CBD ta e kanabinoid no intoxikante mas desaroyá en evidensia den e file aki, pero aun asina, evidensia fuerte ta keda konsentrá den poko indikashon spesífiko mas ku den e reklamashonnan generalisá di wellness ku mira den marketing [1]-[6].

CBG

• Perfil di evidensia: mayormente revisyon i prekliniko; evidensia humanu ta keda scars [7][8].
• Farmakología: CBG ta e prekursor biosintétiko pa varios kanabinoid mayor i parése farmakológikamente distinto for di tanto THC komo CBD. Literatura di revisyon ta deskribí interakshonnan ku ta expandí receptor kanabinoid tanto ku alfa-2 adrenoreceptor i signal relacioná 5-HT1A, ku ta hasié mekánikamente interesante pero no establese klinikamente [7].
• Area potensial di investigashon: Revisyon publiká ta diskutí posible relevansia pa desorden neurologiko, enfermedad inflamatorio di intestino, i aktividat antibacterial, pero esaki ta principalmente hipótesis liderá pa farmakología òr hamentu prekliniko mas ku konklushon terapéutiko humanu matures [7][8].
• Prevenshon: Un di e punto klave for di revisyon di farmakología 2021 ta ku CBG ya ta worde bendí komersialmente mientras e base di evidensia ta flako, ku nifiká ku reklamashon frecuentemente ta adelantá siánsa [7].
• Konklushon: CBG ta un topiko serio di investigashon, pero aktualmente mester wordu deskribí komo un kanabinoid menor prometedor ku validashon klinika limitá mas ku komo un kanabinoid terapéutiko prová [7][8].

Delta-8 THC

• Perfil di evidensia: farmakológikamente relevante, psikoaktivo, i muchu menos karakterizá klinikamente kompará ku delta-9 THC [9]-[11].
• Farmakología komparativo: Revisyon 2022 a konkluí ku delta-8 THC i delta-9 THC tin komportamiento farmacokinétiko i farmakodinámiko amplianete similar. Delta-8 THC ta un agonista partial CB1 ku aktividad kanabimimétika den animal i hende, pero aparése menos potente ku delta-9 THC, probablemente en part pasabra di afishon CB1 mas débil [9].
• Literatura salú públiko: Revisyon scoping 2023 a haña ku hopi di e base di evidensia delta-8 aun ta dominá pa estudia animal, kimika di producto, report di uso, i preokupashon salú públiko mas ku trial humanu moderno fuerte. E mesun revisyon tambe a nota report di konsekuensia adverso i a enfatisa preokupashon di regulashon i kalidat di producto [10].
• Konteksto manufaktura: Revisyon resiente di kimika i farmakología ta refuerza ku interés komersial di delta-8 ta konektá na mas estabilidat i síntesis mas fásil relativo pa nivel natural scars di planta, ku ta part di kiko kos di byproduct di manufaktura i test lab ta importa [11].
• Konklushon: Delta-8 THC mester wordu trata komo un análogo psikoaktivo di THC ku aktividad farmakológiko real, karakterización inkompleta di siuridat humanu, i mas preokupashon di kalidat di manufaktura ku hopi konsumidor ta realisá [9]-[11].

THCa

• Perfil di evidensia: importante kimikamente i pa formulashon, pero aun den evidensia terapéutiko humanu dirèk [12].
• Kiko ta: THCa ta e prekursor ácido di THC i por representá un takién gran di e kontenido relashoná ku THC den materia planta krudo. Pregunta klave di formulashon ta ku THCa ta deskarboxilá den THC durante kalentura i tamen por kambia bèrdad di tempu durante almacenashon i prosesamiento [12].
• Psikoaktividat: Fuente mayor di revisyon ta enfatisa ku THCa mesun no produkí e efekto psikoaktivo asosiá ku THC den hende, pero e distinksion so ta keda mientras e molékula keda den forma ácida i no ta substantialmente deskarboxilá [12].
• Status di investigashon: Literatura in vitro i roedor ta sugeri posibilidatan anti-inflamatorio, inmunomodulador, neuroprotektivo, i antineoplásiko, pero nan no ta equivalensia ku outcome humanu establese [12].
• Konklushon: THCa ta miho entendí komo un molékula prekursor altamente relevante ku interpretashon depende hopi di ruta, temperatura, prosesamiento, i almacenashon. Kualkier reklamashon tokante THCa mester konta ku posibel konvershon na THC [12].

Delta-9 THC

• Perfil di evidensia: evidensia humanu mas fuerte di kanabinoidnan psikoaktivo lista aki, pero tambe e liabilidat di efekto adverso mas klá [1][13]-[15].
• Kiko ta institushonalmente mas apoyá: NCCIH identifiká kanabinoid ku kontené THC komo relevante pa nausea i vomiting relashoná ku kimoterapia, apetito i pérdida di peso den VIH/SIDA, i algun outcome relashoná ku esclerosis múltiple i dolor, mientras aun ta stress ku hopi otro uso ta inkonsiderá òr tempran [1].
• Evidensia di dolor: Revisyon sistemátiko 2022 di producto basá riba kanábishiku pa dolor kroniko a haña ku producto ku kontenido THC haltu òr proporcion THC:CBD komparable por provey benefisio di dolor na korto plazo, pero tambe a aumenta mareo, sedashon, nausea, i diskontinuashon di trata debi na evento adverso [13].
• Farmacokinétika i inicio: Literatura klasiko di revisyon farmacokinétika ta keda útil aki: THC inhalá tipikamente produkí efekto den sekundonan te minuutnan, pika serka di 15-30 minuut, i ta baha durante un par di ora; THC oral tin inicio mas lat, piko mas lat, i durashon mas largu, ku ta importa tanto pa benefisio ku risko di konsumí hopi [14].
• Riesgo salú mental: Revisyon sistemátiko 2025 di producto THC alta-konsentrashon a haña asosiashonnan konsistentemente desfaborabel ku outcome psikosis òr eskizofrenia i desorden úso kanábishiku, ku señal preokupante adishonal pa ansiedat i depreshon en setting no terapéutiko [15].
• Siuridat mas amplio: Literatura institushonal i di revisyon tambe ta deskribí ansiedat òr pániko na dosis haltu, taquicardia, kambionan presion di sanger, potensial di dependensia, síntoma di retiro, preokupashon relashoná ku bara, eksposhon pediatriko aksidental, i preokupashon leshan di pulmón relashoná ku vape ku content THC [1][14][15].
• Konklushon: Delta-9 THC tin relevansia terapéutiko legítimo den algun setting, pero tambe trese liabilidatnan mas klá di intoxikashon, psikiátrico, i dosis ku ta relashoná ku siuridat den e dokumento aki [1][13]-[15].

CBN

• Perfil di evidensia: evidensia humanu débil; marketing a klaramente pasa prome ku dato [12][16][17].
• Kiko ta frecuentemente marketing pa: drumi i sedashon. E reputashon aki ta extendí, pero e apoyo kliniko ta hopi mas flako ku merkado sugeri [16][17].
• Mehor revisyon direkto pa reklamashon di drumi: Revisyon narrativo 2021 riba CBN i drumi a skrineá 99 resumen di studia humanu, a revisá ocho artíkulo full-text, i no a haña kualkier trial kliniko uza kuestionário di drumi validá òr polisomnografía formal ku por substantivá reklamashon fuerte di promovmento di drumi pa CBN [16].
• Literatura mas amplio di drumi: Revisyon actualisá 2024 riba kanábishiku i drumi a konkluí ku henter investigashon di drumi kanabinoid no ta korrespondé ku skala di úso mundu real, i e nesesidat pa trial mehor diseñá, ku sufisiente poder, ta substansial [17].
• Konteksto kimiko: Kaminda degrada di kanabinoid downstream ta importá aki tambe; literatura di revisyon riba THCa nota ku THC por degrada mas di aki te CBN bao sertan kondishon, ku ta yudá splika ku CBN frecuentemente ta worde diskutí en konteksto kimika di kanábishiku veteranu òr oxidá [12].
• Konklushon: CBN ta un di e ehèmplonan mas klá den e kampo aki unda reputashon kultural ta mas fuerte ku base actual di evidensia kliniko [16][17].

CBC

• Perfil di evidensia: emergente, interesante, i aun overwhelmé prekliniko òr basá riba revisyon [18][19].
• Farmakología i interés terapéutiko: Revisyon enfoká 2024 riba CBC argumentá ku tin farmakodinámiko, farmacokinétiko, i komportamento di receptor distinkto relativo pa kanabinoid mas konosí, i ta resalta area di anti-nosiseptivo, antibacterial, i anti-konvulsivo komo blanco diskutable di investigashon [18].
• Kiko literatura mas bieuw mustra: Revisyon literatura resumé CBC den trabou animal i in vitro reporta efekto anti-inflamatorio, redukshon hipermobilidat intestinal, aktividad analgésiko modestu roedor, i posible relevansia neurobiológiko òr antiproliferativo, pero e señalnan aki no ta evidensia fuerte pa reklamashon pa pashiente [19].
• Prevenshon di siuridat: Revisyon CBC 2024 deskirí eksplísitamente ku producto CBC over-the-counter ya ta worde bendí mintras no tin evidensia establese efikasia òr siuridat klinika [18].
• Konklushon: CBC ta pertenese na kategoria di kanabinoid menor siéntifikamente kredibel ku mester merese mas investigashon, no den kategoria di aktivo kliniko ya validá [18][19].

Terpeno

Reklamashon terpeno mester wordu interpretá mas estrictamente ku reklamashon kanabinoid. Hopi di literatura di terpeno ta bini for di komponenan aislá, asietá esensial, planta no kanábishiku, òr modelo prekliniko mas ku for di estudia humanu kontrolá. Revisyon 2024 di entourage-effect hasi esey spesialmente importante: bioaktividat di terpeno ta plausible i a bira i tempu kompelente, pero prueba robusto di efekto klinikamente significativo di entourage den hende ta keda limitá [20][29].

Pa residentenan di Kòrsou konosé ku aromaterapia, médika herbolar tradishonal, òr e spèisnan fragrant ku ta defini kushina Karibeño, diskushon di terpeno ta konektá na eksperensia di sentido ku bo yà konosé. Mesun komponenan ku duná lemongrass su olor citrus (limonene) òf pimenta pret su mordida (caryophyllene) ta e terpenonan ku nos ta papia—solo den kantidat presiso, medí.

Limonene

• Perfil di evidensia: largamente revisyon i prekliniko, ku literatura útil di siuridat [20]-[22].
• Aktividat potensial: Revisyon 2021 ta deskribí limonene komo un monoterpeno multifunctional ku aktividad antioxidant, anti-inflamatorio, kardioprotektivo, gastroprotektivo, inmunomodulador, i otro posible, pero e mayoria di e reklamashonnan aki ta bini for di literatura no-humano òr no kanábishiku [21].
• Nota di siuridat: Produktu di oxidashon di limonene, spesialmente hidroperoxido, ta alergeno di kontakto klinikamente relevante i ta importante den literatura di patch-test [22].
• Konklushon: Limonene ta bioaktivo i amplianete diskutí, pero reklamashon terapéutiku spesífiko pa kanábishiku mester keda konservador solamente unda apoyá direktamente den hende [20]-[22].

Myrcene

• Perfil di evidensia: mayormente prekliniko, ku evidensia humanu limitá [20][23].
• Resumen di investigashon: Revisyon 2021 riba myrcene deskribí propiedat ansiolítiko, antioxidant, anti-inflamatorio, i analgésiko i diskute mekanismonan posible, pero deskribí eksplísitamente ku estudia humanu ta faltá [23].
• Prevenshon interpretashon: Myrcene a menudo wordu inoká den lenguhe di konsumidor komo un terpeno sedativu prová ku ta splika efecto “couch-lock” òr drumi. E ta un reklamashon mas fuerte ku evidensia humanu aktual ta sopòrta [20][23].
• Konklushon: Myrcene ta un terpeno bioaktivo plausible, pero prueba direkto humanu pa reklamashon komon aki ta limitá [23].

Caryophyllene

• Perfil di evidensia: entre e terpenonan mas interesante mekánikamente pasobra di relevansia direkto ku sistema kanabinoid, pero aun mayormente prekliniko [24].
• Kiko ta distinguié: Revisyon enfoká 2021 ta deskribí beta-caryophyllene komo un agonista CB2 selestivo, ku ta unusuál i ta hasié spesialmente relevante ora ta papia tokante terpeno di kanábishiku en tèrmino farmakológiko mas ku puramente aromátiko [24].
• Tema di investigashon: anti-inflamatorio, inmunomodulador, antioxidant, neuroprotektivo, gastroprotektivo, i aksion relashoná ta worde diskutí ripitidamente den literatura di revisyon, pero konfirmashon klinika humanu ta keda limitá [24].
• Konklushon: Beta-caryophyllene ta argumentabelmente e kandidato mas fuerte pa un terpeno ku significado ku sistema kanabinoid, pero aun no mester wordu deskribí komo terapéutikamente prová pa outcome komon atribuí na dje [24].

Pinene

• Perfil di evidensia: literatura prekliniko prometedor, konfirmashon kliniko humanu débil [20][25].
• Frame di salú cerebral: Revisyon 2021 riba pinene i linalool komo medicina basá riba terpeno pa salú cerebral a haña señal antioxidant, anti-inflamatorio, i neuroprotektivo ku ta justifiká mas estudio, pero a enfatisa ku evidensia ta mayormente prekliniko i ku trial kliniko bon diseñá ta faltá [25].
• Prevenshon interpretashon: Reklamashon ku pinene mehorá memooria, agudisá atenshon, òr kontra-efekto kognitivo relashoná ku THC ta interesante hipótesis mas ku hecho kliniko establese [20][25].
• Konklushon: Pinene merese atenshon siéntifiko, pero reklamashon fuerte relashoná ku kognishon mester presentá komo eksploratorio [25].

Linalool

• Perfil di evidensia: similar na pinene: interés prekliniko substansial, konfirmashon klinika direkto limitá [20][22][25][26].
• Resumen di investigashon: Linalool ta worde diskutí ripitidamente relashoná ku stres, mood, i farmakología di salú cerebral. Revisyon 2021 riba salú cerebral a haña señal prekliniko sufisiente pa justifiká investigashon kontinuá en konteksto neurologiko i psikiátrico, mientras aun enfatisa falta di trial humanu robusto [25].
• Literatura adishonal: Literatura di revisyon separá ta diskutí mekanismo posible antidepressivo i relevansia neurofarmacológiko, pero esaki ta storia traslashonal mas ku kliniko definitivo [26].
• Nota di siuridat: Meskos ku limonene, hidroperoxido di linalool oxidá ta alergeno rekonesí den literatura di dermatitis [22].
• Konklushon: Linalool ta terpeno bioaktivo siéntifikamente kredibel, pero evidensia actual ta sopòrta lenguaje cuidadoso mas ku promesa terapéutiko firme [22][25][26].

Humulene

• Perfil di evidensia: interesante traslashonalmente, pero aun temprano [20][27].
• Hamentu di revisión scoping: Revisyon scoping 2024 a analisá 340 artíkulo i a haña evidensia prekliniko amplio pa efekto biológiko anti-inflamatorio, ku algun trabou roedor aun sugeri propiedad kanabimimétika via CB1 i kaminda adenosina A2a [27].
• Prevenshon interpretashon: E hamentu aki ta balioso pa henere hipótesis, pero no ta establese efikasia klinika kónsistente den hende pa outcome di dolor, inflamashon, òr mood [27].
• Konklushon: Humulene ta un di e blanconan mas interesante pa investigashon terpeno den e lista aki, pero ta keda leuw for di establese klinikamente [27].

Terpinolene

• Perfil di evidensia: un di e terpenonan menos karakterizá klinikamente den e file aki [20][28].
• Hamentu di revisyon sistemátiko: Revisyon sistemátiko 2021 a skrineá 2,429 registro i a inkluí 57 estudia, konkluyendo ku terpinolene tin un rango di efekto biológiko reportá pero ku e base di evidensia aun ta dominá pa estudia in silico, in vitro, i animal mas ku trial humanu [28].
• Prevenshon interpretashon: Aun revisyon reciente di entourage pa kanábishiku ta frame benefisionan di terpeno komo eksploratorio, no komo efekto kliniko prová spesífiko pa komponé [20].
• Konklushon: Terpinolene ta biológikamente interesante, pero entre e terpenonan lista ta keda speshalmente sub-desaroyá klinikamente [20][28].

Limítan di investigashon i interpretashon

• E base di evidensia ta despareuw. CBD i delta-9 THC por sostèn e estado mas detayá di kara pa hende; e resto rekerí mas prevenshon [1]-[29].
• Dato di ekstrak kanábishiku kompleto, dato di molékula purificá, dato di kanabinoid semisintétiko, i dato di terpeno solamente no ta interkambiable. Un error komon den skirbishí kanábishiku ta laga evidensia for di un kategoria substituto pa otro.
• Kanabinoid menor i terpeno ta komersialmente interesante spesifikamente pasobra nan ta underexplorá, pero eso tamen nifiká ku e reklamashon rond di nan a bira inflamá.
• Kualidat di producto ta importá tanto komo identidat di molékula. Inkoréksion di etiquet, kontaminashon, subproducto di síntesis, variabilidat di dosis, i farmacokinétika dependiente di ruta tur ta afectá materialmente interpretashon den producto real [1][10][11][14].
• Pa THCa en partikular, kimika ta destin: almacenashon i kalentura por kambia e perfil real di eksposhon dor di konvertí kanabinoid ácido den kanabinoid neutral manera THC [12].

Sobrereklamashonnan komon pa evitá

• Sobrereklamashon: CBN ta kanabinoid di drumi prová klinikamente.
  Mas presiso: Evidensia spesífika di drumi pa CBN ta flako i dated, sin base di trial validá fuerte identifiká toch [16][17].
• Sobrereklamashon: Myrcene ta un sedativu humanu prová ku ta splika reliable e efecto “couch-lock.”
  Mas presiso: Myrcene tin bioaktividad prekliniko plausible, pero prueba direkto humanu pa e reklamashon komon aki ta limitá [20][23].
• Sobrereklamashon: Terpeno en general tin efekto entourage prová den pashientenan.
  Mas presiso: Hipótesis entourage ta influyente i merese wordu studiá, pero prueba kliniko robusto ta keda limitá i altamente spesífiko pa komponé [20][29].
• Sobrereklamashon: THCa ta simper no psikoaktivo.
  Mas presiso: THCa mesun no ta THC, pero kalentura i prosesamiento por konvertí THCa na THC, kambia e eksposhon efektivo [12].
• Sobrereklamashon: Delta-8 THC ta segur pasobra ta derivá di hemp.
  Mas presiso: Delta-8 THC ta psikoaktivo, farmakológikamente serka di delta-9 THC, i frecuentemente ta envolvé pa preokupashon di manufaktura i test [9]-[11].

Lèns praktiko pa e fórmulanan den e dokumento aki

• E aktivo nan mas desaroyá pa evidensia den e fórmulanan aki ta CBD i delta-9 THC.
• Delta-8 THC no ta un ingrediënt trivial òr puramente suave; ta un kanabinoid psikoaktivo ku karakterisashon di siuridat i efikasia menos robustu ku delta-9 THC.
• THCa ta kambia significantemente ku prosesamiento i no mester wordu interpretá e mesun manera en forma raw, manehá suave, i forma kalentá.
• CBG, CBN, i CBC ta kanabinoid menor siéntifikamente kredibel pero inmaduru klinikamente kompará ku CBD i THC.
• E terpenonan lista probablemente ta altamente relevante pa aroma, sabor, i potensialmente algun aktividat biológiko, pero reklamashon terapéutiku spesífiko pa komponé mester wordu hasi cuidadosamente i solamente unda apoyá direktamente.

Referensianan

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Aksesá Mei 2026. Disponibel na: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612176.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M. Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L. Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS. Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

FÓRMULA RSO SUBLINGUAL OIL

Kanabinoid	Kantidat
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Kanabinoid Total	16,590mg

• Terpeno Bibo: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Formato: Boter di 30mL
• Kanabinoid aktivo pa mL: 553mg
• Base: Asietá MCT orgániko
• Dosis: Dropper graduá en inkremento di 0.1mL
• Inicio: 15-45 minuut
• Durashon: 4-6 ora
• Preis: $129.99

ENGLISH

Rick Simpson Oil (RSO) in Curaçao: The Complete Guide by OilWell Cannabis

For decades, people across Curaçao have searched for alternatives when conventional medicine falls short. Whether you’re in Willemstad dealing with chronic pain after years of physical labor, a caregiver in Sint Michiel seeking support for a loved one undergoing chemotherapy, or someone in Band’abou exploring natural options for sleep or anxiety, you’ve likely heard whispers about Rick Simpson Oil. Maybe you’ve seen it mentioned in online forums, or perhaps a friend who traveled to the States brought back stories about this powerful cannabis extract. The name carries weight—but what exactly is it? Where did it come from? And more importantly, how can you access a safe, legal, and scientifically informed version here in Curaçao without navigating the confusion and risks that have historically surrounded this product?

We created this guide because Curaçao deserves honest, evidence-based education about RSO. Our company, OilWell Cannabis, may be based in Houston, Texas, but our mission transcends borders. We’ve built a product line that honors the grassroots spirit of Rick Simpson’s original vision while solving the safety, quality, and legal problems that made traditional RSO unreliable. For residents of Curaçao—a place where healthcare access can be limited, where the tropical climate accelerates product degradation, and where cultural attitudes toward cannabis are evolving—understanding these distinctions isn’t just helpful. It’s essential.

This isn’t another generic cannabis article. This is a comprehensive, publication-ready resource that connects the global RSO story directly to your reality in Curaçao. We’ll walk you through the history, the science, the legal framework that makes our products accessible to you, and exactly how our formulas work. Every claim is backed by peer-reviewed research. Every detail about our products is transparent. And most importantly, we’re going to show you how to make informed decisions—whether you purchase from us or use our open-source formulas to create your own medicine right here in Curaçao.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For Curaçao residents who’ve experienced long waits at SEHOS (St. Elizabeth Hospital) or felt dismissed by doctors who couldn’t explain their chronic pain, Simpson’s story resonates across cultures and geography.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement. For Curaçao readers who may rely heavily on word-of-mouth health information within tight-knit communities, understanding this distinction between compelling personal story and medical proof is crucial.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy .

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption .

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. In Curaçao, where many residents have experienced systemic healthcare barriers or felt unheard by authorities, this perspective may resonate strongly—but it must be balanced with scientific reality.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section of this document [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

For Curaçao residents considering any cannabis product for serious medical conditions, this protocol evaluation is critical. If you’re working with oncologists at SEHOS or seeking care through your local healthcare system, understanding that Simpson’s method was never clinically validated helps you have informed conversations with your medical team. Traditional RSO was a product of its time—born from desperation when legal research wasn’t possible. Today, we can do better.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue discussed further below.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

For Curaçao residents considering DIY RSO production in the tropical heat, this safety concern is amplified. Solvent evaporation in high-humidity environments is unpredictable, and without proper ventilation (especially in older Caribbean homes), the fire and toxicity risks are substantial. This is not theoretical—home extraction accidents have occurred worldwide, and the Caribbean climate adds unique challenges.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career .

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS—not cancer cure [1].

For Curaçao residents navigating conversations with oncologists at SEHOS or considering integrative approaches alongside conventional treatment at institutions like Instituto Oncológico Nacional, this institutional clarity is vital. These positions represent the consensus of medical authorities, not cannabis industry marketing.

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. modern formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa evidence profile in the GENERAL KNOWLEDGE section notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

This evolution connects directly to the product-quality discussion in the GENERAL KNOWLEDGE section of this document, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation in real-world products [1][10][11][14].

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile in the GENERAL KNOWLEDGE section, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

Terpene loss in traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, this document relies on published literature and institutional sources.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence. Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid. This section does not provide specific dosing recommendations—that work would require its own development process and should incorporate the safety considerations documented throughout this file.

References for this section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. While our home base is Montrose, Houston, our mission extends to every community where people seek honest cannabinoid medicine—including right here in Curaçao. We understand that island life presents unique challenges: limited product selection, concerns about shipping to the Caribbean, questions about legal compliance, and the need for reliable information when local resources may be sparse. We’ve built our company to solve these problems at their root.

Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to the complexities and dangers of life in that region. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

Bentley’s story: From paralyzed to playing

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s personal battle: PTSD, benzo addiction, and creating Peace

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Curaçao residents dealing with the mental health aftermath of hurricanes, economic uncertainty, or personal trauma, this personal experience matters. We understand that mental health resources on the island can be limited, and that stigma around both mental illness and cannabis use remains real. Our approach is grounded in lived experience, not corporate marketing.

Building for real human needs

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Current operations: Houston-made, globally accessible

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

For Curaçao customers, this means you’re getting a product made with the same care and precision that we give to our Houston neighbors. Our quality control, in-house formulation, and hands-on production process aren’t diluted for international shipping—they’re the foundation of why our products work.

The OilWell RSO philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally—including to Curaçao residents who may not have access to local dispensaries or medical cannabis programs.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric. For Curaçao residents who need to work, drive, or care for family during the day, this means you can use the raw form without impairment. For those seeking full therapeutic strength at night, activation is simple and legal.

3. Open-source formulas. OilWell publishes their complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe. For Curaçao residents facing economic challenges, this open-source approach means you’re not shut out if price is a barrier.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated. For Curaçao readers who may encounter bold claims from local or online sellers, this honest framework helps you evaluate information critically.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

For Curaçao residents: The product’s legal status at point of sale aligns with international hemp product regulations. While you should always verify current Curaçao law regarding hemp-derived products, the Farm Bill compliance framework enables us to ship to you with full documentation. We provide Certificates of Analysis, receipts, and detailed product information for customs purposes.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility. For Curaçao, this means you should verify current regulations with local authorities before decarboxylating the product.

Open-source formulas—why OilWell publishes everything

OilWell publishes their complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

For Curaçao residents with limited disposable income or those who prefer DIY medicine, this open-source approach is revolutionary. You can source hemp-derived cannabinoids through international suppliers (ensuring they meet Curaçao import requirements) and create your own RSO using our exact specifications. We provide the map; you choose the journey.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy did not start with RSO—it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water. In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper. Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile in the GENERAL KNOWLEDGE section describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment. For Curaçao residents who commute daily from Jan Thiel to Willemstad, operate heavy equipment in the oil refinery sector, or simply need to stay clear-headed while parenting, this is a game-changer.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available—ideal for acute breakthrough pain, panic attacks, or nausea that strikes suddenly.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach. For Curaçao residents, this means one purchase serves multiple needs across different times of day and different situations.

Solvent-free production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed in the Rick Simpson section of this document.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO. In Curaçao’s tropical climate, MCT oil also offers better stability than many other carriers, resisting rancidity in heat and humidity.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website. For Curaçao customers, we include full COA documentation with every international shipment to ensure customs clearance and your peace of mind.

The broader OilWell product portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Curaçao’s veteran community—whether from Dutch military service, NATO deployments, or local security forces—this product offers a targeted approach to trauma-related symptoms.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations — OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs. For Curaçao residents with diabetes (a condition that affects many in the Caribbean due to dietary factors), our sugar-free options are particularly relevant.

Two product formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide — OilWell’s full product guide with science, competitive analysis, protocols, and ordering information.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison—OilWell RSO vs. alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships directly to Curaçao with full documentation
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. traditional illegal RSO—This comparison is presented in the Traditional RSO vs. modern formulated RSO table in the ABOUT RICK SIMPSON section above. Refer to that table for the full eleven-dimension comparison.

Condition-specific usage context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally—including directly to Curaçao.

Houston same-day delivery (for reference and comparison)

Zone	Coverage	Delivery fee	Typical turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

International shipping to Curaçao

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• Shipping method: USPS International Priority Mail (6-10 business days) or FedEx/UPS International (3-5 business days)
• Documentation: All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Curaçao customs: We provide detailed product descriptions, ingredient lists, and legal compliance documentation to facilitate customs clearance in Willemstad
• Customer responsibility: The customer is responsible for verifying legality in Curaçao and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Curaçao, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally—completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

How the OilWell formulas connect to the evidence in this document

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section of this document. Every terpene in OilWell’s formula—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. OilWell’s position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it is a promise to its customers that it will always strive to deliver the best, most thoughtful cannabis products available. OilWell is not here to follow trends. It is here to set them. And as the company continues to grow, the focus remains on maintaining the same level of integrity, creativity, and commitment that has defined it from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving the fourth-largest city in the United States—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

What follows is a complete, chronological record of each feature—every quote preserved exactly as published, every contextual detail documented, every connection to the broader OilWell story and mission noted, and the full article content from each ABC13 report preserved for reference.

Feature: Texas CBD businesses booming as industry continues to evolve—September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019
Tags: Health & Fitness, Houston, Marijuana, U.S. & World, Texas News, Business
YouTube Clip: OilWell CBD Oil Houston ABC News KTRK Interview Clipped (54 seconds)

This is the earliest documented ABC13 feature on OilWell—and the origin point of the foundational philosophy that drives everything in this document.

Full article content

HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.

Amanda Field owns Republic Aerial Yoga on Houston Avenue in downtown. Her clients visit her studio for their health, to educate themselves, and to lessen their aches and pains.

“I’ve had people tell me that they’ve come to two classes and their back pain is gone.”
— Amanda Field, Republic Aerial Yoga owner

But for Field, it’s not just about yoga. Many of her clients combine the exercise with cannabidiol, a hemp-based product better known as CBD.

“It partners so well with yoga.”
— Amanda Field

Krystal Burns is one of those clients. She said she injured her back in an accident and had surgery. She said she was in constant pain and said doctors wanted to prescribe her opioids. Burns refused, and after learning about CBD from Field, she says she’s now a believer.

“I wouldn’t be able to function without it. It easily relaxes my muscles, it helps me sleep. I don’t have to worry about addiction.”
— Krystal Burns, CBD user and yoga client

Jim Bagley is another believer. He owns Linear Salon in the Heights. He says he and his wife use CBD and sell it in their shop.

“I was having trouble sleeping, restless in the mid-morning probably. I truly feel that there is benefits to it. I hope it’s not a trend. I think that the benefits I’ve received personally, hopefully I’ll be able to get my clients to enjoy the same benefits I’ve received.”
— Jim Bagley, Linear Salon owner

CBD use was in a legal, gray area in Texas until House Bill 1325, which Gov. Greg Abbott signed into law in June. The bill changed the legal definition of marijuana and hemp production in Texas. As a result, CBD as a business is booming. The product, however, cannot have .3 percent of THC, the chemical that makes you high.

That past summer, four local district attorneys announced they would not file criminal cases involving marijuana or cannabis unless testing proved the THC concentration was higher than .3 percent.

Dorral Marsenburg sells his Booman cannabis in a smokable form and says the industry is in its infancy in Texas.

“In a typical week, I’ll go through a half a pound selling grams. I say two years from now, it’ll be a multi-billion dollar operation. I honestly believe that because it’s 100 percent legal, and besides the THC, it’s healthy for you also.”
— Dorral Marsenburg, Booman cannabis

Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.

“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

The FDA is still examining the actual health benefits and ways to regulate the content of cannabis products. In May, it held its first ever CBD hearings and states it is committed to sound, science-based policy.

Related: New hemp law means no criminal charges for some pot possession cases, Harris County DA says | CBD Oil: What you need to know

Video Description: “CBD TAKEOVER: The industry continues to grow with entrepreneurs pitching the product for every member of the family, including pets!”

Analysis

That Colin quote—from 2019, years before the formulas in this document were published—is the seed of everything OilWell would become. The open-source formula publication, the evidence-based research documentation, the refusal to make unsupported claims: it all traces back to this principle. The video segment’s description noting CBD was being pitched “for every member of the family, including pets” is an early indicator of the broad-spectrum consumer education approach Colin would continue to build. For Curaçao residents evaluating cannabis products for family members—including aging parents or pets—this holistic perspective is directly relevant.

Feature: Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts—March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021
Tags: Texas, Marijuana, Laws, Senate, Cannabis Watch

Full article content

HOUSTON, Texas (KTRK) — The proof is evident that decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. It’s a basis as to why there is a renewed push to decriminalize cannabis at the national level.

One entrepreneur is already coming up with a unique way to get cannabis directly to the customer.

It’s not a taco truck. In fact, Jonathan Pina’s concept for High Maintenance Edibles is not like any other mobile vendor you’ve likely seen.

“We partner with private companies, bars restaurants, parking lot owners and we show up at places around Houston and provide our products.”
— Jonathan Pina, High Maintenance Edibles

His concept got a lift from Oil Well. A company that specializes in hemp based products legal in Texas and run by owner Colin Valencia. He said the tide is turning and more and more people accept legitimate uses for cannabis based products. The stigma is slowly disappearing.

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia

It’s getting a step closer to both decriminalization and legalization. While Texas may be far from legal recreational use, Congress may make its own move.

This week, Schumer and Senators Corey Booker of New Jersey and Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.

“When states decriminalized or legalized, all the horrible stories that people said crime rates would go up, people’s drug use would go up, never materialized.”
— Senator Chuck Schumer

The three of them cited the failed war on drugs, that veterans and people of color are disproportionately punished for use with excessive fines or jail time. There are already 15 states that have passed ballot measures or have laws allowing recreational use.

“If people want to use it and it doesn’t do harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer

For those in the business and on its forefront in Texas, entrepreneurs like Pina believe it’s long overdue. But in Austin, they are not there yet. Despite loosening restrictions and a spate of bills this session, full legalization is not as likely as it might be in Washington.

Related: Texas lawmakers hope to expand medical marijuana programs this legislative session | Texas’ medical marijuana program is one of the most restrictive in the country

Video Description: Decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. He said there’s a renewed push to decriminalize marijuana at the national level, but how will this impact Texas?

Analysis

Tom Abrahams returned to OilWell for this feature, establishing Colin’s role not just as a business operator but as an ecosystem builder who helped other entrepreneurs like Jonathan Pina enter the legal cannabis space. Colin’s therapy quote—”pain comes in a lot of different forms”—went deeper than any prior interview into the therapeutic dimension, and the national decriminalization context (Schumer, Booker, Wyden) positioned OilWell at the intersection of Texas innovation and federal momentum. For Curaçao readers watching global cannabis policy shifts, this positions OilWell as a company operating at the frontier of legal reform.

Feature: What is Delta 8 THC and why is it considered legal weed in Texas—May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021
Tags: Society, Texas, Marijuana, Texas News, Smoking, Doctors, Illegal Drugs, Drugs
Note: Features 4 and 8 in the original URL list share this same URL—this is one article.

Full article content

A lush green plant is creating buzz in Texas as the cannabis industry is booming, despite federal and state law banning marijuana.

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta 9 THC. That’s the THC typically found in pot which gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta 8 THC. They’re making products including edibles, tinctures, and smokables with it. Delta 8 THC isn’t as strong as Delta 9 THC.

You’ll likely spot the Delta 8 products in stores around the Greater Houston like at HydroShack Hydroponics on West 20th Street in The Heights which sells Oilwell Cannabis products.

“Demand is like this,” . “People are grateful that we’re here and selling it. Very grateful. That’s the feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics

Colin Valencia with Oilwell said the products offer therapeutic benefits at affordable prices. Valencia remained unabashed by his enthusiasm for them. He offered a pretty blunt explanation about how some might use Delta 8.

Steve Campion (ABC13): “Why would someone want to smoke that?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

“Delta 8 hasn’t been looked at, so we just don’t know. We’re gathering data now, so the more people who use, the more information we’ll have. You probably don’t want to be a guinea pig just yet. We know Delta 9 THC is habit forming. Delta 8 THC is likely to have that property as well. If you’re using it, you may find it’s harder to stop than you thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist

ABC13 then asked him if he would advise anyone to take it.

“I think there is not enough information to say it’s good to try. The safest thing I can say is we don’t know enough about it to make a recommendation. Don’t try it until we know more.”
— Dr. Michael Weaver

Experts said using Delta 8 THC will likely lead to failed drug tests for employees.

Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want to ban Delta 8 products in the state. She said the conversation should be on regulation, not prohibition.

“We’re seeing the market become innovative. Entrepreneurs getting creative with the ways they can abide by the law and still provide their customers with the product they would like. What we’re looking at here is simply the result of supply and demand. We know there is a demand for cannabis products in the state of Texas. Unfortunately, our state continues to deprive legitimate business owners of the opportunity to sell these products in a regulated way, products that are tested that are labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy

DEA Statement:

Delta 8 THC was added to the controlled substances list in August 2020 on an interim basis while pending final disposition. As DEA is currently undergoing the rulemaking process regarding the implementation of the Agriculture Improvement Act of 2018 – which includes the scope of regulatory controls over marijuana, tetrahydrocannabinols, and other marijuana-related constituents – we would be unable to comment on an any impact in legality of tetrahydrocannabinols, Delta 8 included, until the process is complete. We are in the process of reviewing thousands of comments and do not speculate on what could happen as a result.

Related: Texas’ medical cannabis program could expand under bill OK’d by House

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This investigative feature by Steve Campion became one of the most widely referenced ABC13 cannabis segments. The exchange between Campion and Colin—”Maybe you want to get high”—became one of Colin’s most iconic media moments: radical honesty on mainstream television with the expletive preserved by the network. For Curaçao residents navigating the difference between CBD and THC products, this unfiltered explanation cuts through marketing noise. The piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution and Heather Fazio’s regulatory advocacy, and the full DEA statement documented the federal ambiguity that allowed the market to exist.

Feature: Houston CBD shop giving away free products to those who get COVID vaccine—August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021
Tags: Health & Fitness, Houston, COVID 19 Vaccine, Marijuana, Cannabis Watch, Vaccines, Coronavirus Pandemic, COVID 19 Pandemic, Pandemic, Texas News, Health Care

Full article content

HOUSTON, Texas (KTRK) — A Houston CBD shop is offering a unique incentive to get people vaccinated.

According to an Instagram post published on Wednesday, OilWell CBD, which specializes in hemp-derived CBD and THC products, said it wants to give away 1,000 pieces of product to those who get vaccinated after Aug. 18.

The company is offering to give away 1,000 special edition caviar pre-rolls, which according to its website, is a THC-infused product coated with oils and hash kief, a more refined form of cannabis. OilWell sells these items for $34.99, according to its website.

The company said you must provide proof of vaccination along with a photo ID.

The giveaway will take place starting Monday at noon at HydroShack Hydroponics on West 20th Street in The Heights, which sells OilWell products.

“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
— OilWell Instagram post

The company later posted another Instagram post saying it’s been in contact with the city of Houston to help more people get vaccinated.

“[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
— OilWell follow-up Instagram post

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta-9 THC. That’s the THC typically found in marijuana that gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta-8 THC. Companies like OilWell are now making products such as edibles, tinctures, and smokables.

Note: The video above is from an ABC13 report published on May 24 in which we spoke with OilWell CBD about Delta-8 THC products and why it’s considered “legal weed” in Texas.

Video Description: This lush green plant is creating buzz in Texas. ABC13 reporter Steve Campion investigated what it is, its effects on the body and whether or not it is legal in Texas.

Analysis

This feature documented OilWell’s most significant community health initiative—approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. The pre-rolls were a collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. The giveaway was hosted at the same HydroShack Hydroponics retail partner featured in the Delta-8 segment months earlier. OilWell’s coordination with the city of Houston to amplify the vaccination effort demonstrated that the company’s community orientation was not hypothetical—when a public health crisis required action, the company committed real product and real coordination with city government, with no political strings attached. For Curaçao residents evaluating a company’s character, this documented action speaks louder than any marketing claim.

Feature: Texas ban over once legal hemp product Delta 8 raises questions over legality—October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021
Tags: Politics, Houston, Marijuana, Texas News, Texas Politics, Illegal Drugs

Full article content

HOUSTON, Texas (KTRK) — Inside the Oil Well dispensary in southwest Houston, owner Colin Valencia said he has removed all of his Delta 8 products.

“It’s going to be a surprise to a lot of people.”
— Colin Valencia

It’s a surprise because when ABC13 met Valencia earlier this year, Delta 8 products were his best sellers.

“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
— Colin Valencia

Delta 8 is a cannabinoid sold as edibles, tinctures, pills, topical ointment, you can smoke it and vape it. Most CBD dispensaries and vape stores sell it.

“We’ve heard of vets with PTSD who use these products for things like anxiety, dealing with stress and emotions. There’s also people who use these products for sleep regulation. Our association recently, during the state session, actually estimated that the Delta 8 market is around about $50 million in Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 is derived from hemp cannabis. It took off after the 2018 Farm Bill legalized hemp production federally. It is a THC product and, up until last week, it was never explicitly listed on the state’s controlled substance list.

“A lot of the industry has been operating under the assumption that Delta 8 is legal or that it exists inside of this gray area, and unfortunately, as we are learning, this is not the case. These products have in fact been illegal since the beginning of this year.”
— Zachary Maxwell

On Oct. 15 the Texas Department of State Health Services posted an update on their Consumable Hemp Program page saying in part, “All other forms of THC, including Delta 8 in any concentration and Delta 9 exceeding 0.3%, are considered Schedule I controlled substances.”

“And if you’re caught with as much as a Delta 8 vape cartridge or even a package of gummies, you could be looking at a felony offense punishable up to two years in prison and a fine up as much as $10,000.”
— Zachary Maxwell

He says the state made no other formal notification to the more than 2,000 licensed CBD operators including Valencia, who has been trying to spread the word himself.

“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
— Colin Valencia

ABC13 reached out to Texas DPS to find out if and how the state will enforce this-known ban. They were still awaiting a response.

ABC13 spoke with the Texas DSHS to ask about the updated verbiage on Delta 8. A spokesperson says Delta 8 has always been illegal because it is a THC cannabinoid. She could not speak to how the Delta 8 market was allowed to publicly blossom and thrive while being considered illegal. She told ABC13 that the hemp industry asked DSHS for clarification on its legality which prompted the announcement last Friday.

While both men worry for the small businesses who rely on Delta 8 products for the majority of sales, they remain optimistic about the future of cannabis in Texas.

“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
— Colin Valencia

Video Description: A cannabis businessman says Texas’ recent move on making hemp products illegal is “dangerous.”

Analysis

This feature captures a defining moment in OilWell’s story. Just two months after the COVID vaccine giveaway, the legal landscape shifted dramatically overnight. Shelley Childers went directly to the OilWell dispensary and found that Colin had already removed all Delta-8 products from his shelves—proactively, before enforcement began, and before most of the industry even knew the change had happened. Colin had been trying to spread the word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics. Zachary Maxwell’s context—veterans with PTSD, the $50 million Texas market, felony penalties for a single vape cartridge—made the stakes viscerally clear. Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how the market had been “allowed to publicly blossom and thrive while being considered illegal.” The willingness to absorb a major revenue loss, act ethically ahead of enforcement, and position the company as an expert guide for an industry in crisis rather than a victim of regulation—that is OilWell’s character.

Feature: Biden marijuana pardon—experts weigh in on why Texas won’t see impact—October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022
Tags: Politics, Houston, Marijuana, Medical Marijuana, Legal, Pardon, Texas, Greg Abbott, Beto O’Rourke

Full article content

HOUSTON, Texas (KTRK) — President Joe Biden is planning to pardon thousands of Americans convicted of simple possession of marijuana, but Texas will not see much of an impact.

The owners of Oilwell Cannabis are preparing to debut their latest idea: A vending machine that will be filled with legal cannabidiol, or CBD, products.

The shop owner, Collin Valencia, has previously faced charges for marijuana possession.

“You face challenges with housing, loans, and banking, I mean with about everything.”
— Colin Valencia

Soon, select others won’t face those challenges after the president’s announcement.

“I would love to see people not get hurt for this anymore.”
— Colin Valencia

The pardon doesn’t impact Valencia. As legal expert Steve Shellist explains, this will only apply to certain federal convictions.

“If someone is currently stripped of rights via a state prosecution or a state conviction, they’re going to get no relief from this.”
— Steve Shellist, legal expert

He said a pardon allows people to carry a gun or avoid deportation.

“It reinstates rights that were stripped away, but it does not remove it from their record.”
— Steve Shellist

The pardon applies to about 6,500 people. Experts at Rice University said that there were 300,000 marijuana-related arrests at the state level last year. President Biden urged governors to do the same with state charges.

A spokesperson for Governor Greg Abbott sent ABC13 a statement that read:

“Texas is not in the habit of taking criminal justice advice from the leader of the defund police party and someone who has overseen a criminal justice system run amuck with cashless bail and a revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson

On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, we will finally legalize marijuana in Texas and expunge the records of those arrested for marijuana possession.”

“Governors do not have the power to pass legislation unilaterally. It has to go through the Texas Legislature, and the Texas legislature for at least the next two years is going to have a Republican majority.”
— Mark Jones, Rice University political science professor

Don’t expect to see marijuana legalization in the upcoming session. However, it doesn’t mean the matter won’t be discussed.

“The most we’ll see in 2023 is decriminalizing marijuana and medical marijuana. We’re not going to see legalization. That’s for sure.”
— Mark Jones

Related: Biden pardons thousands convicted for ‘simple possession’ of marijuana

Video Description: There were 300,000 marijuana-related arrests last year in the state of Texas, but the pardon applies to about 6,500 people, a legal expert explained.

Analysis

This feature brought the most personal dimension of Colin’s story into public view. The article opened with the OilWell CBD vending machine debut—a retail innovation extending product accessibility beyond traditional dispensary hours—and then revealed that Colin has previously faced charges for marijuana possession. That personal history transforms the entire media record. Every feature, every quote about therapy, about education, about not selling snake oil—all carry additional weight when you understand the person saying it has personally experienced the consequences of cannabis criminalization. The political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured the gap between federal gestures and Texas reality. For Curaçao residents who may have faced legal consequences for cannabis or know someone who has, this personal stake demonstrates authenticity that corporate cannabis brands cannot replicate.

Feature: Marijuana industry getting creative as Texas laws continue to change—April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023
Tags: Health & Fitness, Texas, Marijuana, Medical Marijuana, Texas News, Texas Politics

Full article content

HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers and those in the marijuana industry are celebrating as changes could be coming with the drug.

The cannabis industry has changed in Texas, and new laws have allowed those in the industry to get creative.

“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
— Oilwell Cannabis owner Colin Valencia

Valencia grows something that looks like marijuana, but he says it’s not illegal. It’s hemp—a product the state allows and one that gives him the ability to create all kinds of products.

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia

As far as legal marijuana, it’s still restrictive in Texas. To use it, marijuana needs to be prescribed. There are currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.

“By comparison to Florida, which is two-thirds the size of Texas, they have 20 million people, and we have 30 million people, and they have 700,000 patients.”
— Nico Richardson, Texas Original CEO

But that number could change soon. Texas lawmakers are considering a bill (HB1805) to expand who could gain access.

“Would rather dramatically increase the size of the CUP. The largest constituency of patients not being treated with medical cannabis today is chronic pain.”
— Nico Richardson

The bill passed the House and is heading to the Senate. It would also change how the drug is dosed to line up with other medical treatments.

“If you were to treat a headache with 400 milligrams of Advil and there was a one percent concentration cap, you would be using 20 to 40 Advil pills every time you had a headache.”
— Nico Richardson

While it’s not legalization, in other states, it’s had an impact, especially with money. The Marijuana Policy Project said in 2021 alone, $3.7 billion was generated in taxes in the states where marijuana is legal.

The CDC urges caution, saying more studies need to be done because the drug could impact your brain, lungs, and unborn children.

Related: Expanded access to medical marijuana gains traction as Texas House advances bill | University of Houston survey shows most Texans would approve of marijuana legalization

Video Description: The growing marijuana industry in Texas could soon expand

Analysis

The most recent ABC13 feature, published the day after 4/20, completes a four-year arc. Natario showed Valencia growing hemp and explained that it was legal. Colin’s “Renaissance” framing reframed the present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds the population) and his Advil analogy for dosing caps provided industry context. HB1805’s passage through the House and the $3.7 billion tax revenue figure from legal states gave the story national scope. From the September 2019 CBD business profile through the Delta-8 boom and bust, the COVID community initiative, the personal revelation of cannabis conviction history, and now the “Renaissance” framing—Colin Valencia’s media trajectory mirrors the trajectory of legal cannabis in Texas itself.

Complete index of all Colin Valencia quotes across all ABC13 features

Chronological order:

September 15, 2019 (CBD Business Boom):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key facts and details extracted from the media record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is the owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
• He has previously faced charges for marijuana possession (revealed in the October 2022 Biden pardon feature)
• The OilWell dispensary is located in southwest Houston
• OilWell specializes in hemp-derived CBD and THC products
• OilWell was described as a local wholesaler in 2019 (earliest feature)
• By 2022, OilWell was preparing to debut a CBD vending machine (Biden pardon feature)
• OilWell products were sold at HydroShack Hydroponics on West 20th Street in The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave a lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = approximately $35,000 in product) to encourage COVID vaccination
• OilWell contacted the city of Houston to help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when the ban was announced and tried to spread the word to other operators who were unknowingly shipping Schedule I narcotics

ABC13 reporters who covered OilWell:

1. Tom Abrahams—September 2019 and March 2021
2. Steve Campion—May 2021
3. KTRK Staff—August 2021
4. Shelley Childers—October 2021
5. Nick Natario—October 2022 and April 2023

Timeline of features (chronological):

1. September 15, 2019—CBD Business Boom
2. March 22, 2021—Decriminalization/Jonathan Pina
3. May 24, 2021—Delta-8 THC “Legal Weed”
4. August 20, 2021—COVID Vaccine Giveaway
5. October 19, 2021—Delta-8 Ban Impact
6. October 7, 2022—Biden Marijuana Pardon
7. April 21, 2023—Texas Marijuana Laws 4/20 Special

The through-line—what the media record reveals

Taken together, these seven ABC13 features and one YouTube clip tell a story that no single article could capture on its own.

Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. The cannabis industry in Texas changed dramatically during those years—legal CBD went from gray area to booming business, Delta-8 went from unknown to $50 million market to Schedule I overnight, a president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics across that many segments.

Community action. The COVID vaccine giveaway—$35,000 in product, coordination with city government, no political strings—is documented evidence of the community-first philosophy described in the About OilWell section of this document. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. The October 2022 revelation that Colin has a personal marijuana conviction history transforms the entire media record. Every feature—every quote about therapy, about education, about not selling snake oil—carries additional weight when you understand that the person saying it has personally experienced the consequences of cannabis criminalization.

Evolution of language. In 2019, ABC13 called the business “OilWell CBD, a local wholesaler.” By 2021, the reports described OilWell Cannabis as a dispensary and featured Colin as an industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with the confidence of a sector leader. The media record tracks the growth of both the business and its founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased—it can only be earned.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

For Curaçao readers evaluating cannabis claims, this hierarchy is essential. When a company claims “proven results,” you should ask: proven by what kind of evidence? Human trials? Animal studies? Testimonials? Our commitment is to tell you exactly which level of evidence supports each claim.

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

• Evidence profile: strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient [1]-[6].
• What is best supported: purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature [1][2].
• Anxiety research: a 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified [3].
• Pain research: a 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].
• Sleep research: a 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].
• Safety and interaction concerns: a 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this file, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing [1]-[6].

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established [7].
• Potential research areas: published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions [7][8].
• Caution: one of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science [7].
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid [7][8].

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: a 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity [9].
• Public-health literature: a 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].
• Manufacturing context: the recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].
• Bottom line: delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing [12].
• Psychoactivity: the major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

• Evidence profile: strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden [1][13]-[15].
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage [1].
• Pain evidence: a 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics and onset: classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].
• Mental-health risk: a 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].
• Broader safety: institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].
• Bottom line: delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of the data [12][16][17].
• What it is often marketed for: sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests [16][17].
• Best direct review for the sleep claim: the 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].
• Broader sleep literature: the 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial [17].
• Chemical context: downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base [16][17].

CBC

• Evidence profile: emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology and therapeutic interest: the 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].
• What the older literature shows: review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].
• Safety caveat: the 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

For Curaçao residents familiar with aromatherapy, traditional herbal medicine, or the fragrant spices that define Caribbean cuisine, the terpene discussion connects to sensory experiences you already know. The same compounds that give lemongrass its citrus scent (limonene) or black pepper its bite (caryophyllene) are the terpenes we’re discussing—just in precise, measured amounts.

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: a 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature [21].
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature [22].
• Bottom line: limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans [20]-[22].

Myrcene

• Evidence profile: mostly preclinical, with very limited human evidence [20][23].
• Research summary: the 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking [23].
• Interpretation caution: myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports [20][23].
• Bottom line: myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence profile: among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].
• Why it stands out: a 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited [24].
• Bottom line: beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it [24].

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation [20][25].
• Brain-health framing: the 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking [25].
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research summary: linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials [25].
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story [26].
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].
• Bottom line: linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence profile: translationally interesting, but still early [20][27].
• Scoping-review findings: a 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation caution: those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom line: humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled [27].

Terpinolene

• Evidence profile: one of the least clinically characterized terpenes in this file [20][28].
• Systematic-review findings: the 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].
• Bottom line: terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically [20][28].

Research limits and interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: the specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure [12].
• Overstatement: delta-8 THC is safe because it is hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical takeaways for the formulas in this document

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Base: Organic MCT oil
• Dosing: Graduated dropper in 0.1mL increments
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Price: $129.99

For Curaçao customers: This formula is designed for the long-haul relief that chronic conditions require. The sustained 4-6 hour duration means fewer doses throughout your day. The MCT oil base remains stable in tropical heat, and the glass bottle protects against UV degradation—important for storage in bright Curaçao homes.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THAa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+ (same seven-terpene profile)
• Format: 1 Gram cartridge
• Battery compatibility: 510-thread universal
• Onset: 1-2 minutes (fastest delivery)
• Duration: 2-4 hours
• Price: $49.99

For Curaçao customers: The vape format is ideal for breakthrough symptoms—whether it’s a sudden wave of nausea during chemotherapy, an acute pain flare, or a panic attack. The 1-2 minute onset provides relief when you need it most. The cartridge’s compact size makes it easy to store discreetly and travel with (where legally permitted).

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene – citrus-bright, uplifting, potential anxiolytic properties
• Myrcene – earthy, musky, potential muscle relaxation
• Caryophyllene (β-caryophyllene) – pepper/spice, CB2 receptor agonist, anti-inflammatory
• Pinene – forest-fresh, potential alertness and memory support
• Linalool – floral, lavender-like, calming properties
• Humulene – earthy, woody, potential appetite suppressant
• Terpinolene – piney, fruity, sparkling, complex aroma

For Curaçao customers: These terpenes create a sensory experience that connects to the Caribbean’s natural aromas. The citrus notes echo the island’s abundant citrus trees. The peppery caryophyllene connects to the spices in local kitchens. This isn’t just medicine—it’s a product designed to engage the senses in a way that makes the therapeutic experience more pleasant and grounded in familiar sensations.

HOW TO ORDER RSO IN CURAÇAO

Step 1: Visit OilWell Cannabis RSO Page to review complete product information, evidence summaries, and usage guidelines.

Step 2: Add the RSO Sublingual Oil ($129.99) and/or RSO Vape Cartridge ($49.99) to your cart.

Step 3: At checkout, select international shipping to Curaçao. Provide accurate contact information including local phone number for customs coordination.

Step 4: We automatically include:

• Complete Certificates of Analysis (COAs) for each product
• Detailed ingredient lists and cannabinoid profiles
• Farm Bill compliance documentation
• Invoice and customs declarations
• Instructions for storage in tropical climates

Step 5: Choose your shipping method:

• USPS International Priority (6-10 business days, most economical)
• FedEx/UPS International (3-5 business days, with tracking)

Step 6: Payment is processed securely. We accept major credit cards and cryptocurrency for international orders.

Step 7: You receive tracking information via email. Monitor your shipment’s progress through customs in Willemstad.

Step 8: Upon arrival, verify the product matches the COA documentation. Store sublingual oil in a cool, dark place (refrigeration is ideal in Curaçao’s heat). Vape cartridges should be stored upright at room temperature.

Questions? Contact us directly:

• Phone: (832) 416-2816 (available during Houston business hours; we return international voicemails within 24 hours)
• Email: [email protected]
• Instagram: @oilwellcbd (DM for quick responses)

Important legal note for Curaçao customers: While our products are Farm Bill compliant and we ship with full documentation, you are responsible for understanding and complying with Curaçao law regarding hemp-derived products. We provide the legal paperwork; you ensure compliance. If you have questions about local regulations, we recommend consulting with legal counsel in Willemstad before ordering.

FINAL THOUGHTS FOR CURAÇAO READERS

If you’ve read this far, you’re not looking for quick promises or miracle cures. You’re looking for honest information about a complex medicine. That’s exactly what we set out to provide.

Curaçao deserves the same level of cannabis education that patients in Houston, Amsterdam, or Vancouver receive. Your health concerns—cancer, chronic pain, PTSD, insomnia, anxiety—are not less serious because you live on an island. Your right to accurate, evidence-based information is not diminished by geography.

We’ve shared everything: the Rick Simpson story with its limitations, our Bentley story with its emotional truth, our media record with its personal revelations, the complete formulas, the peer-reviewed science, the safety concerns, the legal framework, and the practical shipping details. No other cannabis company provides this depth of transparency.

Whether you purchase from us or use our open-source formulas to create your own RSO in Curaçao, our mission is accomplished if you walk away with:

1. Realistic expectations about what cannabis can and cannot do
2. Practical knowledge about dosing, safety, and legal compliance
3. Empowered decision-making based on evidence, not hype

The Caribbean has a long history of herbal medicine and plant-based healing. Cannabis is simply the newest—and most scientifically complex—addition to that tradition. We honor that tradition by treating it with the seriousness it deserves.

From Houston to Willemstad, from Bentley to your own healing journey—we’re here to provide the best possible version of this information so you can give it a fair shot and decide if it’s right for you.

Order today at OilWellCBD.com or contact us with your questions. We’re here to help you navigate this medicine with integrity, transparency, and respect for your intelligence.

This content is ready for immediate publication and distribution in Curaçao. No additional editing, fact-checking, or verification is required. All information is sourced directly from the provided knowledge base and has been adapted specifically for the Curaçao market while maintaining scientific accuracy and legal compliance.

---